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Abstract 
PI3K- and mTOR-dependent mechanisms of lapatinib resistance and  
resulting therapeutic opportunities 
 
Samuel Warren Brady, BS 
Supervisory Professor: Dihua Yu, MD, PhD 
 
Breast cancers with HER2 amplification represent 20-25% of breast cancer cases and are 
frequently responsive to the HER2 kinase inhibitor lapatinib, but generally for only short 
duration. We aimed to understand how breast cancers with HER2 amplification become 
resistant to lapatinib, in order to identify potential therapies that can overcome lapatinib 
resistance. To establish lapatinib resistance models we treated three HER2+ breast cancer 
cell lines with lapatinib for several months until they became lapatinib-resistant. We then 
compared lapatinib-sensitive (parental) cells with their lapatinib-resistant (LapR) 
counterparts to identify changes conferring lapatinib resistance. We found that activation of 
PI3K, specifically the p110α catalytic subunit, was enhanced in two out of three LapR cell 
lines, through p110α activating mutations and/or upregulation. In a third LapR cell line, 
mTOR activation was enhanced in a manner independent of its usual PI3K/Akt-mediated 
activation or other known mTOR activators. Thus, all three cell lines possessed increased 
activation of the PI3K/mTOR pathway, suggesting the use of PI3K and/or mTOR inhibitors 
in lapatinib-resistant breast cancers. We found that p110α-specific PI3K inhibition 
effectively overcame lapatinib resistance in LapR cell lines and xenografts with increased 
p110α activation, while the LapR cell line with PI3K-independent mTOR activation was 
 vi 
 
sensitive to mTOR inhibition but resistant to PI3K inhibitors. mTOR activation in lapatinib-
resistant breast cancer cells was accompanied by increased levels of the inhibitors of 
apoptosis (IAP) family, which could be reversed by the mTOR kinase inhibitor AZD8055 or 
the Hsp90 inhibitor 17-AAG. Together these data strongly suggest the use of PI3K/mTOR 
inhibitors or Hsp90 inhibitors to prevent or delay lapatinib resistance. Further, we found that 
p110α-specific PI3K inhibition in combination with lapatinib was both effective against 
LapR xenografts and well-tolerated in mice. Thus pan-PI3K inhibition may not be necessary 
for some lapatinib-resistant patients, thus sparing them the toxicities of inhibition all four 
class I PI3K isoforms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
Table of Contents 
 
Dedication…………………………………………………………………………………...iii 
Acknowledgements………………………………………………………………………….iv 
Abstract……………………………………………………………………………………….v 
Table of Contents…………………………………………………………………………...vii 
List of Figures………………………………………………………………………………..ix 
List of Tables………………………………………………………………………………....x 
 
Chapter 1. Introduction……………………………………………………………………….1 
1.1. Overview…………………………………………………………………………1 
1.2. HER2…………………………………………………………………………….1 
1.3. PI3K……………………………………………………………………………..4 
1.4. mTOR……………………………………………………………………………5 
1.5. HER2 targeted therapy…………………………………………………………..6 
1.6. Lapatinib…………………………………………………………………………7 
1.7. Lapatinib resistance……………………………………………………………...8 
1.8. PI3K/mTOR inhibitors…………………………………………………………..9 
 
Chapter 2. Materials and Methods………………………………………………………….11 
 2.1. Cell lines………………………………………………………………………..11 
 2.2. Phospho-RTK array..…………………………………………………………...11 
 2.3. Reverse phase protein array…………………………………………………….12 
 2.4. Whole-exome sequencing...…………………………………………………….12 
 2.5. Western blot analysis……………………...……………………………………12 
 2.6. Fractionation of cellular compartment...………………………………………..13 
 2.7. Quantitative PCR……………………………………………………………….14 
 2.8. Transfection and transduction………………………………………………….14 
 2.9. MTT assay and crystal violet staining.……………….………………………...15 
 2.10. Cell cycle analysis………………………………….…………………………16 
 2.11. Animal studies………………………………………………………………...16 
 2.12. Small-molecule inhibitors……………………………………………………..17 
 
Chapter 3. PI3K p110α promotes lapatinib resistance, which can be reversed by lapatinib in    
                  combination with BYL719……………………………………………...………18 
3.1. Introduction……………………………………………………………………..18 
3.2. Development of lapatinib resistance models and quantification of lapatinib    
       sensitivity………………………………………………………………….……19 
3.3. BT474 and UACC893 lapatinib-resistant cell lines possess enhanced PI3K 
       p110α activation………………………………………………………………..21 
3.4. PI3K E542K-mutant cells represent the majority or founding clone in  
       BT474 LapR cells………………………………………………………………28 
3.5. The p110α but not p110β PI3K subunit is necessary for lapatinib resistance 
       in lapatinib-resistant cell lines………………………………………………….31 
3.6. PI3K p110α activation is sufficient to promote lapatinib resistance…………...34 
 
 viii 
 
3.7. p110α is upregulated through DNA amplification or post-transcriptional 
       upregulation in lapatinib-resistant cell lines……………………………………36 
3.8. The p110α-specific PI3K inhibitor BYL719 effectively reverses lapatinib 
       resistance in combination with lapatinib in vitro………...……………………..38 
3.9. BYL719 in combination with lapatinib effectively overcomes lapatinib 
       resistance in vivo……………………………………………………………….44 
3.10. Summary of chapter 3…………………………………………………………49
  
Chapter 4. Lapatinib-resistant cells are dependent on PI3K-independent  
      mTOR activation………………………………………………………………..50 
 4.1. Introduction…………………………………………………………………….50 
 4.2. AU565 lapatinib-resistant cells possess PI3K-independent mTOR activation...50 
 4.3. AU565 lapatinib-resistant cells are sensitive to mTOR but not 
                   PI3K inhibition…………………………………………………………………55 
 4.4. S6 phosphorylation in AU565 lapatinib-resistant cells is Rheb- and 
                   mTOR-dependent but independent of known upstream Rheb activators……....57 
 4.5. Mutational analysis of AU565 parental and lapatinib-resistant cell lines suggests 
                   that multiple subtle mutations may play a role in lapatinib resistance…………60 
 4.6. Multiple inhibitors of apoptosis (IAPs) are increased in AU565 lapatinib- 
                   resistant cells and mTOR inhibition reverses IAP expression……………..…...65 
 4.7. Hsp90 inhibition reverses IAP expression and inhibits growth of  
                   AU565 lapatinib-resistant cells…………………………………….…………...69 
4.8. Summary of chapter 4……………………………………………….………….70  
 
Chapter 5. Discussion……………………………………………………………………….74 
 
Appendix……………………………………………………………………………………82 
Bibliography………………………………………………………………………………...91 
Vita………………………………………………………………………………………...104 
 
 
 
 
 
 
 
 
 ix 
 
List of Figures 
 
Fig. 1. HER2 signaling mechanisms in HER2+ breast cancer……………………………….3 
Fig. 2. BT474 and UACC893 LapR cell lines are markedly lapatinib-resistant……………20 
Fig. 3. BT474 LapR cells do not possess activation of alternative RTKs…………………..22 
Fig. 4. Genomic and proteomic analyses suggest enhanced PI3K p110α level and 
           activation in LapR cells……………………………………………………………...23 
Fig. 5. PI3K p110α protein and downstream signaling is increased in LapR cells…………25 
Fig. 6. PI3K membrane localization is maintained in LapR cells after lapatinib treatment...27 
Fig. 7. PI3K E542K mutation exists in all single-cell clones of BT474 LapR cells 
           analyzed……………………………………………………………………………...30 
Fig. 8. Knockdown of PI3K p110α sensitizes LapR cells to lapatinib……………………...32 
Fig. 9. Crystal violet stain confirms that knockdown of PI3K p110α, but not p110β, 
           sensitizes LapR cells to lapatinib…………………………………………………….33 
Fig. 10. PI3K p110α activation is sufficient to promote lapatinib resistance……………….35   
Fig. 11. PI3K p110α increases in LapR cells through diverse mechanisms………………...37 
Fig. 12. BYL719 overcomes lapatinib resistance in combination with lapatinib…………...40 
Fig. 13. Lapatinib plus BYL719 effectively blocks the PI3K-Akt pathway………………..41 
Fig. 14. Lapatinib plus BYL719 inhibits the cell cycle and induces cell death 
             in LapR cells………………………………………………………………………..43 
Fig. 15. Lapatinib plus BYL719 inhibits the growth of LapR xenografts ………………….45  
Fig. 16. Lapatinib plus BYL719 effectively inhibits the PI3K-Akt and Erk pathways……..47 
Fig. 17. Lapatinib plus BYL719 inhibits Akt phosphorylation and heterogeneously 
              inhibits Erk phosphorylation in LapR xenografts………………………………….48 
Fig. 18. AU565 LapR cells are markedly lapatinib-resistant……………………………….52 
Fig. 19. AU565 LapR cells possess Akt-independent S6 phosphorylation…………………53 
Fig. 20. AU565 LapR cells maintain 4E-BP1 hyperphosphorylation under lapatinib 
             treatment compared to parental cells……………………………………………….54 
Fig. 21. AU565 LapR cells have lost dependence on PI3K but not mTOR………………...56 
Fig. 22. Known mTOR activation mechanisms are not involved in mTOR activation  
             in AU565 LapR cells……………………………………………………………….58 
Fig. 23. PI3K-independent S6 phosphorylation in AU565 LapR cells is Rheb- and 
             mTOR-dependent…………………………………………………………………..59 
Fig. 24. Copy-number variations in AU565 LapR cells compared to parental cells………..62 
Fig. 25. FKBP38 and Rb1 loss are not sufficient to promote lapatinib resistance………….63 
Fig. 26. mTOR activation promotes IAP expression in AU565 LapR cells………………...68 
Fig. 27. Hsp90 inhibition reverses expression of some IAPs and reverses lapatinib  
              resistance in AU565 LapR cells……………………...……………………………71 
Fig. 28. Model of changes in apoptotic signaling in AU565 LapR cells……………………72 
Fig. 29. Model of mechanisms of lapatinib resistance identified…………………………...73 
 
 
 
 
 x 
 
List of Tables  
 
Table 1. BT474 RPPA Data…………………………………………………………………82  
Table 2. UACC893 RPPA Data……………………………………………………………..86 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
Chapter 1. Introduction 
 
1.1. Overview 
Breast cancer consists of multiple subtypes, and among the most aggressive breast 
cancers historically are the 20-25% with HER2 (ERBB2) gene amplification (1). Although 
HER2-targeted therapies have significantly improved the prognosis of this group, acquired 
resistance to HER2 targeted therapies remains a significant challenge (2, 3). Lapatinib, a 
HER2 kinase inhibitor used to treat HER2+ breast cancers, is generally effective for one 
year or less in the metastatic setting (4). The purpose of the research described here was to 
determine how HER2+ breast cancers become resistant to lapatinib and, through this 
understanding, identify and test potential treatment options for these patients.   
 
1.2. HER2 
HER2 is a receptor tyrosine kinase in the EGFR family. It is encoded at the ERBB2 
locus on chromosome 17, and most cases of HER2 overexpression are due to ERBB2 copy 
number increase (5). This frequently results in oncogene addiction in HER2+ breast cancers, 
which are often very sensitive to HER2-targeted therapy (6). Trastuzumab, an anti-HER2 
monoclononal antibody that inhibits HER2 dimerization with EGFR, HER3, or other HER2 
molecules, was the first FDA-approved HER2 targeting agent (1998), with the approval of 
lapatinib, a small-molecule kinase inhibitor, coming later in 2007 (7, 8). T-DM1, which is 
trastuzumab fused to the chemotherapeutic emtansine (a derivative of maytansine), has 
recently shown dramatic efficacy in clinical trials for the treatment of HER2+ breast cancer 
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(9). Our laboratory has a strong interest in understanding why some HER2+ breast cancers 
do not respond to HER2-targeting agents (10, 11).  
Of note, HER2 is unique in the EGFR family of RTKs (which consists of EGFR, 
HER2, HER3, and HER4) because it has no known ligand (12); thus HER2 is dependent on 
other members of the family (EGFR and HER3) for activation after they bind to ligand. 
Thus when EGFR or HER3 are activated by ligand binding (by EGF or heregulin, for 
example), HER2 acts as the highest affinity co-receptor to EGFR and HER3, frequently 
leading to EGFR-HER2 and HER2-HER3 heterodimers, which leads to trans-
phosphorylation of the heterodimers and activation of downstream signaling pathways 
(especially the PI3K and  MAPK pathways) (13). However, when HER2 is overexpressed 
through gene amplification, HER2-HER3 heterodimers occur in a ligand-independent 
manner (14) due to dramatically increased concentration of HER2 (15-fold or more (15)) at 
the cell membrane (see Fig. 1 for a summary of HER2 signaling in HER2+ breast cancer). 
HER2’s oncogenic function is largely due to heterodimerization and phosphorylation 
of HER3, which possesses a remarkable 6 PI3K docking (activation) sites (16). Knockdown 
of HER3 or PI3K inhibition effectively inhibits the growth of HER2+ breast cancers, which 
indicates the importance of the PI3K pathway in this type of breast cancer (see Fig. 1). 
Moreover, the efficacy of HER2-targeting agents is largely dependent on the inhibition of 
the PI3K pathway, without which tumor growth continues unabated (4, 17). Various 
mechanisms of HER2-independent PI3K activation have been shown to confer resistance to 
trastuzumab or lapatinib (10, 18–20).  
 
  
  
Figure 1. HER2 signaling mechanisms in HER2+ breast cancer. Genetic amplification of 
the gene encoding HER2 leads to high levels of the receptor at the cell surface and ligand
independent homodimerization and heterodimerization with other family members. 
Dimerized receptors trans-autophosphorylate the C
HER2 is represented as having no ligand
HER3 is the primary PI3K-activating protein in the family a
when HER2 is overexpressed. HER3 does not reciprocate phosphorylation to HER2 as it is 
relatively kinase-dead (13). Phosphorylation of HER2 and EGFR leads to recruitment of 
proteins such as SOS (among many others), which activates the MAPK pat
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-terminal tails of dimerization partners. 
-binding domain due to lack of a known ligand. 
nd is phosphorylated by HER2 
hway. 
-
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1.3. PI3K 
 Arguably the most important function of HER2 is to promote PI3K activation (14, 
21). As mentioned, this occurs primarily as HER2 heterodimerizes with HER3 and 
phosphorylates HER3’s 6 PI3K docking sites. These docking sites include a 
phosphotyrosine with a methionine three amino acids C-terminal to the phosphotyrosine 
(pYXXM) (22). The p85 subunit of PI3K recognizes these phosphotyrosine motifs and this 
leads to the recruitment of p85-p110 (the PI3K holoenzyme) to the cell membrane (23). p85 
binding to HER3 leads to conformational changes that releases p85’s inhibition of the p110 
catalytic domain of PI3K. p110 is then activated to phosphorylate its lipid substrate at the 
cell membrane, phosphoinositide-4,5-bisphosphate (PIP2), to form the second messenger 
phosphoinositide-3,4,5-bisphosphate (PIP3). PIP3 is recognized by the pleckstrin homology 
(PH) domain of PDK1, Akt and other cytosolic proteins and thus recruits these proteins to 
the cell membrane. PDK1 then phosphorylates and activates Akt and other targets, which 
promote cell proliferation and survival (23, 24).  
 The p85 regulatory and p110 catalytic subunits of PI3K each come in several forms 
encoded by different genes. p85 isoforms include p85α (PIK3R1), p85β (PIK3R2), and p55γ 
(PIK3R3) (25). p110 comes in at least four different isoforms, but in epithelial cells (and 
breast cancers) the two ubiquitiously-expressed forms are p110α (PIK3CA) and p110β 
(PIK3CB). Both appear to play important roles in breast cancer: PIK3CA mutations resulting 
in constitutive PI3K/p110α activation are present in 25-30% of breast cancers, including 
some 30% of HER2+ breast cancers (26). PIK3CB/p110β mutations are not frequently 
observed in cancer; however, loss of the PIP3 phosphatase PTEN, which thus negatively 
regulates PI3K signaling, appears to be driven primarily by p110β rather than p110α (27). 
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Importantly, there is evidence that HER2+ breast cancers with HER2/HER3-
independent activation of PI3K, such as through PI3K mutations (18, 19), PTEN loss (18), 
or activation of alternative RTKs (20), are resistant to HER2-targeting agents such as 
lapatinib. This is likely because HER2-targeting agents do not lead to inhibition of PI3K-
Akt signaling in these tumors, which is maintained by alternative sources such as other 
RTKs or PI3K mutations. Loss of PTEN, a negative regulator of PI3K signaling, was 
previously shown by our laboratory to promote resistance to the HER2-targeting antibody 
trastuzumab, due to the inability of trastuzumab to block PI3K-Akt signaling in such cancers 
(10). Our work described herein describes additional PI3K-dependent mechanisms by which 
HER2+ breast cancers may become resistant to HER2-targeted agents.   
 
1.4. mTOR 
 The mechanistic target of rapamycin (mTOR) is another important player in HER2+ 
breast cancers. Our laboratory previously showed that trastuzumab in combination with the 
mTOR inhibitor RAD001 (everolimus) is effective in preclinical models of trastuzumab 
resistance (28), and this led to a successful clinical trial of this drug combination in HER2+ 
breast cancer (29).  
 mTOR is a large (~290 kDa) serine-threonine kinase that promotes survival 
signaling, protein translation, nutrient sensing, and many other cellular processes considered 
important for cancer progression (30). mTOR is activated by PI3K-Akt signaling in part 
through Akt-mediated phosphorylation of TSC2 (31). TSC1 and TSC2 function as a 
heterodimeric GTPase for the GDP/GTP-binding protein Rheb, which is active in its GTP-
bound state and inactive when GDP-bound (32). Akt-mediated phosphorylation of TSC2 
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leads to inactivation of the TSC1/2 GTPase and thus increases Rheb GTP loading and 
activation. mTOR binding to active (GTP-bound) Rheb is essential for mTOR’s kinase 
activity towards various substrates, including its protein translation-associated targets 4E-
BP1 and P70 S6K (30). 4E-BP1 binds to and inactivates the protein elongation factor eIF4E, 
except when phosphorylated by mTOR. P70 S6K leads to phosphorylation of the S6 
ribosomal protein, which promotes translation of a specific subclass of transcripts thought to 
promote cell proliferation (33, 34). Thus mTOR activation works on multiple levels to 
promote protein translation processes that would favor cancer growth. 
 Our work described herein describes a PI3K-independent mTOR activation 
mechanism by which HER2+ breast cancers may become resistant to lapatinib.   
 
1.5. HER2 targeted therapy  
 The concept of HER2 targeted therapy originated in the 1980s when Slamon and 
colleagues identified overexpression of HER2 on some 25% of breast cancers (5). This was 
followed by the pioneering work of Genentech on the first HER2-targeted therapy, the 
humanized monoclonal antibody trastuzumab (marketed as Herceptin) (35), which was 
approved by the FDA for HER2+ breast cancer in 1997. Trastuzumab binds to the 
juxtamembrane extracellular region of HER2 and interferes with ligand-independent 
receptor homodimerization and heterodimerization (14, 36). Trastuzumab’s approval was a 
landmark event in the field of targeted therapy and the drug has dramatically improved the 
prognosis of HER2+ breast cancer, particularly when used in neoadjuvant and adjuvant 
settings (2, 7).  
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 The approval of trastuzumab has been followed by the development of other HER2-
targeting agents, including the dual EGFR/HER2 kinase inhibitor lapatinib (8) and later the 
covalent pan-HER kinase inhibitor neratinib (37), as well as the trastuzumab fusion drug T-
DM1 (9), which is fused with the chemotherapeutic emtansine. 
      
1.6. Lapatinib 
Lapatinib is a small-molecule kinase inhibitor that blocks the kinase activity of 
EGFR and HER2 by competing for ATP binding in the catalytic cleft of these kinases (38). 
It is among the most specific kinase inhibitors ever developed and has minimal known off-
target effects (39). It was originally designed by GlaxoSmithKline for the treatment of 
EGFR-associated lung cancer (40), but it was found to effectively inhibit HER2 and was 
thus repurposed for breast cancer (41).   
Lapatinib shows the great efficacy in treatment-naïve (newly diagnosed) HER2+ 
breast cancers in the neoadjuvant (pre-surgical) setting (42). When used in this setting in 
combination with trastuzumab and docetaxel, lapatinib doubled the pathological complete 
response (pCR) rate to therapy from 34% (trastuzumab + docetaxel) to 68% (lapatinib 
followed by trastuzumab + docetaxel). pCR indicates that no cancerous tissue is evident by 
pathological analysis in tissue removed after surgery and frequently correlates strongly with 
improved survival or even “cure” (43). Thus lapatinib has the potential to significantly 
improve survival in the neoadjuvant setting. In metastatic breast cancer, particularly 
metastatic breast cancer previously treated with trastuzumab (8), the outcomes are 
significantly worse (44). Lapatinib treatment after progression on trastuzumab results 
increased progression-free but not overall survival (8). Additionally, in responding patients, 
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acquired resistance often occurs in which an initial response is followed by therapy failure, 
which usually occurs within one year of the start of treatment (45). This raises the question 
as to why some HER2+ breast cancers respond to lapatinib while others do not, and how 
some initially responsive tumors later become resistant. The answers to these questions are 
likely to suggest additional therapeutic options for these patients.  
 
1.7. Lapatinib resistance 
Various lapatinib resistance mechanisms have been proposed, most of which involve 
HER2-indendent PI3K activation (4). PI3K mutation, PTEN loss, estrogen receptor (ER) 
upregulation, activation of alternative RTKs (such as AXL), and upregulation of HER3 itself 
have been reported in preclinical lapatinib resistance models and/or patient specimens (18–
20, 46). Some of the drugs or drug combinations proposed to target these resistance 
mechanisms are known or likely to possess significant toxicity. For example, in PI3K-
mutant or PTEN-null lapatinib-resistant tumors, the PI3K inhibitors suggested for use in 
these cases are known to have significant toxicities (47), and that toxicity may be 
compounded when used with lapatinib as targeted therapy combinations at times result in 
unexpected toxicities (48). Thus alternative therapeutic strategies are needed. 
One additional and perhaps less-recognized mechanism of lapatinib resistance is 
incomplete inhibition of HER2 and HER3 phosphorylation by lapatinib. Indeed, in one 
clinical study, only 40% of patients treated with lapatinib experienced a decrease in 
phosphorylated HER2 of more than 50% (49). Thus the combination of trastuzumab and 
lapatinib has been proposed to more effectively block HER2 and its downstream targets, and 
clinical experience indicates that this combination is significantly more effective than either 
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drug alone (42, 50). The difficulty of blocking HER2 may be partly due to its high 
expression in HER2+ breast cancer (through gene amplification), requiring a higher 
concentration of drug to block the receptor compared to those drugs targeting mutant kinases 
that are expressed at endogenous levels. Indeed, clinical evidence suggests that genetically 
amplified oncoproteins are more difficult to target than non-amplified ones (51, 52).    
Of note, many lapatinib resistance mechanisms also confer trastuzumab resistance, 
including PI3K mutations and PTEN loss (4, 18, 53). Thus insights into lapatinib resistance 
may also lead to enhanced understanding of trastuzumab resistance.   
 
1.8. PI3K/mTOR inhibitors 
 Inhibitors of the PI3K/mTOR pathway have been developed at a rapid pace in recent 
years (54), due to the frequent alterations of this pathway in a wide variety of cancers (55). 
Unfortunately, however, dose-limiting toxicities have limited their efficacy by preventing 
sufficient dosage to completely or mostly inhibit the intended targets (47). Indeed, PI3K 
plays an essential physiological role in the insulin pathway of glucose metabolism, and PI3K 
inhibitors can lead to diabetes-like symptoms as an on-target toxicity (47, 56). Likewise, 
mTOR is at the crossroads of numerous cell signaling processes, including nutrient sensing, 
protein translation, autophagy regulation, hypoxia, growth factor signaling, and many others 
(30), and mTOR kinase inhibitors, such as AZD8055 (57) and others (58), tend to have 
significant toxicities. Thus, better approaches are needed to target this pathway. 
 To help mitigate the toxicities of PI3K/mTOR inhibition, isoform-specific PI3K 
inhibitors that target only the p110α or p110β catalytic subunits of PI3K have been 
developed (59–61). Most PI3K inhibitors are “pan-PI3K” inhibitors, block the p110α, 
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p110β, p110δ, and p110γ subunits (54). (The latter two subunits are primarily expressed in 
hematopoietic lineages and play important roles in immune function (62).) However, many 
cancers only depend on one PI3K/p110 subunit, such as PIK3CA-mutant cancers in which 
p110α, but not other subunits, is the prime driver of PI3K activity (59, 63). Thus, p110α-
specific PI3K inhibitors are thought to have greater potential than pan-PI3K inhibitors in 
such cancers by reducing toxicities and thus allowing the highest possible dosage and 
inhibition of the real target of interest (24).     
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Chapter 2. Materials and Methods 
 
2.1. Cell lines 
 UACC893 and AU565 cells were from ATCC while BT474 is derived from the 
tumorigenic BT474.m1 sub-line, which was a kind gift from Dr. Dajun Yang (28). Cell lines 
were cultured in DMEM/F12 in 9% FBS. Lapatinib-resistant cells were generated by 
treatment of cells with 2.1µM lapatinib for at least 6 months (BT474 and AU565) or 
increasing doses of lapatinib until reaching 2.1µM for 5 months (UACC893). Lapatinib was 
withdrawn for at least one week prior to experiments with LapR cells. All cell lines were 
authenticated by the MD Anderson Characterized Cell Line Core by short tandem repeat 
(STR) fingerprinting; all LapR cells were correctly considered to be equivalent to their 
parental cell counterparts by the Core’s analysis. All cell lines were tested for mycoplasma 
every 3-5 months using Lonza’s MycoAlert Mycoplasma Detection Kit and were found 
mycoplasma-negative in each case.    
 
2.2. Phospho-RTK array 
 Cells were treated with drugs and harvested per instructions for R&D’s human 
phospho-RTK array kit or Cell Signaling’s PathScan RTK Signaling Antibody Array Kit 
(Chemiluminescence Readout). Briefly, cells were lysed in lysis buffer and lysate was added 
to arrays containing capture antibodies. Arrays were washed and incubated with detection 
antibody cocktails recognizing phosphorylated proteins. After additional washes arrays were 
analyzed by ECL reagents (Pierce).  
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2.3. Reverse phase protein array  
 Cells were harvested in RPPA lysis buffer prepared according to instructions from 
the MD Anderson RPPA Core. Protein was harvested and diluted to 1 to 1.5µg/µL. Protein 
was boiled in 1x loading buffer and submitted to the MD Anderson RPPA Core for data 
acquisition and normalization.  
 
2.4. Whole-exome sequencing 
 Genomic DNA was isolated from parental and LapR cells and was submitted to 
Otogenetics Corporation for whole-exome sequencing. Otogenetics performed exome 
capture by NimbleGen V2 or Agilent V5 capture and performed sequencing by Illumina 
HiSeq2000. Data were uploaded to the DNANexus online tool for analysis.   
 
2.5. Western blot analysis 
 After treatment with drugs as indicated, monolayer cultures were placed on ice in 
cold PBS and cells were scraped, centrifuged, and lysed in ice-cold lysis buffer (5mM 
EDTA; 150mM NaCl; 50mM Tris, pH 8.0; 1% Triton X-100; 0.1% SDS with PhosSTOP 
and protease inhibitor cocktail). After at least 15 minutes of lysis, lysates were cleared by 
centrifugation at maximum speed at 4º C for 15 minutes. Cleared lysate protein content was 
quantified by BCA assay, and samples were diluted to 1µg protein per µL and boiled in 1x 
loading buffer (from 6x loading buffer composed of 0.25M Tris, pH 6.8; 8% SDS; 40% 
glycerol; 10% β-mercaptoethanol freshly added; and a small amount of bromophenol blue) 
for 10 minutes. 30µg per sample was loaded and run by SDS-PAGE and transferred to 
nitrocellulose (or occasionally PVDF) membranes by semi-dry transfer (Bio-Rad). Samples 
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were blocked in 5% milk in PBS-T or TBS-T for 30 minutes. Milk was washed twice in 
PBS-T or TBS-T for 5 minutes per wash. Primary antibodies diluted (generally at 1:1000 or 
more dilute) in 5% BSA in PBS-T or TBS-T were added to the membranes and incubated 
overnight at 4º C. Membranes were washed three times in PBS-T or TBS-T for 5-10 minutes 
each and then HRP-conjugated secondary antibodies (diluted 1:3000 in 5% milk in PBS-T 
or TBS-T) were added. After 1-3 hours of incubation in secondary antibody, membranes 
were again washed three times in PBS-T or TBS-T and incubated in enhanced 
chemiluminescence (ECL) reagents (Pierce) and exposed to film. If re-probing with 
additional antibodies was needed, membranes were washed briefly with PBS-T or TBS-T 
and additional primary antibodies were added. Occasionally membranes were cut to 
facilitate probing of one membrane with multiple antibodies at the same time.  
 Antibodies used were from Cell Signaling, except for GAPDH and Rheb (Santa 
Cruz), E-cadherin (BD), β-actin and α-tubulin (Sigma), and FKBP38 (R&D). Quantification 
of bands, when performed, was done using ImageJ.  
 
2.6. Fractionation of cellular compartments 
 Membrane/cytosolic fractionation was performed (after indicated treatments) by 
washing off medium with PBS, followed by addition of cold sucrose-containing buffer (250 
mM sucrose, 20mM HEPES at pH 7.4, 10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM 
EGTA, 1mM DTT, and protease inhibitor cocktail from Sigma) on ice. Cells were scraped, 
centrifuged, and lysed by passing cells through an 18 to 27 G needle 10 to 15 times to 
disrupt plasma membrane but not nuclear membrane. Nuclear fraction was removed by 
centrifuging at 720 x g for 5 minutes and collecting the supernatant (which contained 
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mitochondrial, membrane, and cytosolic fractions). Mitochondrial fraction was removed by 
centrifuging at 10,000 x g for 5 to 10 minutes and harvesting the supernatant (which 
contained membrane and cytosolic fraction).  
If membrane-only fraction was desired, membrane/cytosolic fraction was centrifuged 
at 100,000 x g for 1 hour. Supernatant (cytosolic fraction) was removed and stored on ice 
and membrane pellet was washed in 1-3mL sucrose buffer and centrifuged again at 100,000 
x g for 45 minutes. Supernatant was removed and membrane pellet was resuspended in 
western blot lysis buffer, sonicated, and then quantified for protein content by BCA assay. 
Cytosolic fraction protein was concentrated using Microcon tubes (with 10 kDa molecular 
weight cutoff filter to retain proteins of that size; Sigma) and quantified by BCA assay. 30µg 
of cytosolic, membrane, or cytosol/membrane fraction was analyzed by SDS-PAGE and 
western blot.     
 
2.7. Quantitative PCR 
 RNA or genomic DNA (gDNA) was harvested from cells using RNAzol RT or 
TRIzol (for RNA) or the PureLink Genomic DNA Mini Kit (for gDNA; Life Technologies). 
cDNA was generated from RNA using SuperScript III Reverse Transcriptase (Life 
Technologies). qPCR was performed using KAPA SYBR FAST or Bio-Rad iQ SYBR 
Green Supermix.  
 
2.8. Transfection and transduction 
 siRNA from Sigma was transfected using PepMute siRNA transfection reagent 
(SignaGen) and fresh medium was given the next day. For analysis of knockdown 
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efficiency, protein or RNA was harvested 3 days post-transfection. For MTT assays, drug or 
vehicle was given the day after siRNA transfection, followed by MTT assay 3 days later. 
 For stable transduction, lentivirus was generated by transfecting 293FT cells with 
equal amounts of PMD2G and psPAX2 plasmids encoding lentivirus packaging proteins as 
well as the plasmid encoding the protein of interest. Lentivirus was filtered with a 0.45µm 
filter and added to target cells in 1:1 fresh medium with 5-8µg/mL polybrene to enhance 
transduction efficiency. Infected cells were selected for by ZsGreen/GFP expression (flow 
cytometry) or treatment with appropriate antibiotics for 3-7 days.  
 Human HA-PIK3CA wild-type and H1047R constructs were subcloned from 
Addgene plasmids 12522 and 12524 (kindly deposited by Dr. Jean Zhao (64)), respectively, 
using Infusion HD cloning (Clontech), into pLVX-EF1a-ZsGreen (Clontech). The PIK3CA 
E542K mutant was generated by site-specific mutagenesis using Infusion HD cloning.  
 
2.9. MTT assay and crystal violet staining 
 MTT assay and crystal violet staining was used to analyze cell number. For MTT 
assay, 3,000 to 10,000 cells per well were plated in 96-well plates in 100µL of complete 
medium. The next day, siRNA or drug was added. Drug was given at 2x concentration in 
100µL to make a final volume of 200µL of 1x drug with cells. 3-5 days after the addition of 
drug, MTT assay was performed as follows. 20-30µL per well of 5mg/mL of MTT (Sigma) 
dissolved in completed medium (filtered) was added per well. After 1-3 hours of incubation 
in MTT at 37º C in a cell culture incubator, medium was removed from wells and 100µL of 
DMSO was added per well to dissolve formazan crystals. After dissolution of formazan, 
plates were read at OD570 minus OD650 using a plate reader. Data were normalized to 
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vehicle control (=100%). For crystal violet staining, cells were plated in 6-well plates. 
300,000 cells were plated in each well or cells were plated empirically. siRNA was added 1-
2 days later, followed by addition of drug the following day. In some cases siRNA 
transfection was repeated 3 days after initial transfection. After 3-6 days of treatment with 
siRNA and drug, cells were fixed and stained with 0.5% crystal violet and 6% 
glutaraldehyde for 30 minutes. Solution was removed and wells were washed, dried, and 
imaged using a Zeiss SteREO microscope.    
  
2.10. Cell cycle analysis 
 Cells were treated with drugs as indicated, and cells were harvested, fixed in ice-cold 
75% ethanol/25% PBS for 40 minutes. Cells were then washed, and propidium iodide was 
added at 33µg/mL in PBS. After 20 minutes at 37º C cells were analyzed by flow cytometry 
and data were analyzed using FlowJo software. Cell doublets were removed from analysis.   
 
2.11. Animal studies 
 Xenografts were established by injecting 4.5 million BT474 LapR cells into female 
Swiss nude mice (two mammary fat pads (mfps) per mouse, which were from MD 
Anderson’s Department of Experimental Radiation Oncology). Cells were injected in 1:1 
serum-free medium/growth factor-reduce Matrigel (BD). Mice were 6-8 weeks old at the 
time of injection. 7 days after injection mice were randomized to the four treatments and 
tumors were measured (day 0). On day 1 treatment started with lapatinib at 48 mg/kg (from 
GlaxoSmithKline and LC Laboratories), BYL719 at 48mg/kg (from Novartis), both drugs, 
or vehicle. Vehicles used were 0.5% hydroxypropylmethylcelluose, 0.1% Tween-20 
 17 
 
(lapatinib vehicle), or 0.5% methylcellulose (BYL719 vehicle). Each animal received equal 
volumes of both vehicles in each treatment. BYL719 and lapatinib dosage was reduced to 36 
mg/kg after we observed dryness in the muzzle area of BYL719 and combination mice. 
However, this dryness soon disappeared and lapatinib dose was increased to 48mg/kg on 
day 9 and BYL719 dose remained at 36mg/kg for the remainder of treatment. For tumor 
western blot analysis, four tumors per treatment (from two mice) were removed one week 
after start of treatment, approximately 5 hours after that day’s drug treatment, for western 
blot analysis and IHC. To aid in tumor establishment and maintenance, estradiol injections 
were given one day after tumor injection and on days 2, 12, 22, 33, and 44. The formula 
(length x width2) / 2 was used to calculate tumor volumes. Tumor length and width were 
analyzed using calipers on indicated days. Mouse weight was determined using a scale. Per 
MD Anderson IACUC regulations, animals were sacrificed once cumulative tumor diameter 
exceeded established thresholds. 
 
2.12. Small-molecule inhibitors 
 Small-molecule inhibitors used were from LC Labs (lapatinib), GlaxoSmithKline 
(lapatinib), Novartis (BYL719), or Selleck (MK2206, GDC0941, RAD001, temsirolimus, 
BEZ235, AZD8055, and 17-AAG). 
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Chapter 3. PI3K p110α promotes lapatinib resistance, which can be reversed by 
lapatinib in combination with BYL719 
(Findings in this chaper have been published in the following research article: Brady 
SW, Zhang J, Seok D, Wang H, and Yu D. Enhanced PI3K p110α Signaling Confers 
Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective 
PI3K Inhibitor. Molecular Cancer Therapeutics 13:60-70 (2014). Permission was granted 
by the journal to reprint figures from that publication here.) 
 
3.1. Introduction 
 As reviewed in Chapter 1, lapatinib resistance is a clinical challenge in HER2+ 
breast cancer. In order to study acquired lapatinib resistance, we developed isogenic pairs of 
lapatinib-sensitive and lapatinib-resistant cell lines and compared them biochemically. 
Lapatinib-resistant cell lines were developed by treatment of lapatinib-sensitive, HER2+ 
breast cancer cell lines for an extended time. Based on our molecular studies of these 
lapatinib-resistant cell lines we identified drug combinations that can effectively reverse 
lapatinib resistance. We developed a total of three lapatinib-sensitive/lapatinib-resistant 
pairs of cell lines. In this chapter, we discuss two lapatinib-resistant cell lines that show a 
PI3K-dependent lapatinib resistance phenotype. The third cell line, which is mTOR- but not 
PI3K-dependent, is discussed in Chapter 4.  
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3.2. Development of lapatinib resistance models and quantification of lapatinib 
sensitivity 
 We established lapatinib-resistant (LapR) breast cancer cell lines by treatment with 
2.1µM lapatinib (or increasing doses of lapatinib until reaching 2.1µM lapatinib) for at least 
5 months. These were generated from BT474.m1 (BT474 hereafter), AU565, and UACC893 
HER2-amplified breast cancer cell lines. (Ping Li generated the BT474 and AU565 LapR 
cell lines.) AU565 LapR cells are discussed in Chapter 4 while BT474 and UACC893 LapR 
cells are discussed in this chapter.  
 We quantified the degree of lapatinib resistance of each cell line by treating them 
with lapatinib for 4 days, followed by MTT assay (Fig. 2). We found that the lapatinib IC50 
of BT474 LapR cells was dramatically higher than BT474 parental counterparts (~4µM for 
LapR compared to ~50nM for parental), while for UACC893 LapR cells the IC50 was not 
reached as compared to ~300nM for UACC893 parental. These data indicate that LapR cells 
are indeed lapatinib-resistant. In addition, LapR cells continued to proliferate rapidly in the 
presence of 2.1µM lapatinib, whereas parental cells are highly sensitive to this concentration 
of lapatinib.  
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Figure 2. BT474 and UACC893 LapR cell lines are markedly lapatinib-resistant. BT474  
and UACC893 parental and LapR cell lines were treated with indicated concentrations of 
lapatinib for 3 (UACC893) or 4 (BT474) days, followed by MTT assay. O.D. indicates 
optical density and is an indicator of cell number. All MTT assay readings were normalized 
to DMSO control (=100%). Error bars, SEM. 
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3.3. BT474 and UACC893 lapatinib-resistant cell lines possess enhanced PI3K p110α 
activation 
As activation of alternative receptor tyrosine kinases (RTKs) that function 
redundantly to HER2 is thought to promote resistance to HER2-targeted therapies (4, 65), 
we analyzed the phosphorylation (activation) of RTKs in BT474 parental versus LapR cells 
using two different phospho-RTK array platforms (Cell Signaling, Fig. 3A; R&D, Fig. 3B). 
This assay utilizes a sandwich ELISA approach: spotted capture antibodies on a membrane 
bind to proteins from cell lysates, while a detection antibody cocktail recognizing tyrosine 
phosphorylation sites and specific serine/threonine phosphorylation sites allows detection of 
phosphorylated proteins using chemiluminescence (66). However, our analysis did not 
reveal any significantly increased phospho-RTKs in LapR cells compared with parental cells 
(Fig. 3A, B). Importantly, however, the Cell Signaling array included antibodies recognizing 
phosphorylated Akt and S6 as well, and BT474 LapR cells appeared to possess enhanced p-
Akt and p-S6 under lapatinib treatment compared to parental cells (Fig. 3A), suggesting that 
the PI3K/Akt/mTOR signaling may be enhanced in LapR cells. (p-S6 is downstream of 
mTOR and is indicative of mTOR activation (30).) 
To identify potential mechanisms of lapatinib resistance, we compared parental and 
LapR cell lines biochemically using reverse phase protein array (RPPA) to analyze ~170 
proteins and phosphoproteins in parental versus LapR cells. We found that PI3K p110α 
protein level was increased in BT474 LapR and UACC893 LapR cells (Fig 4A). (For 
complete RPPA data please see Supplemental Table 1 for BT474 and Supplemental Table 2 
for UACC893 RPPA data in the Appendix.) 
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Figure 3. BT474 LapR cells do not possess activation of alternative RTKs. BT474 parental 
and LapR cell lines were analyzed by phospho-RTK arrays from Cell Signaling (A) or R&D 
(B). In (A) cells were treated for 4 hours with DMSO or 1µM lapatinib. In (B) assay was 
performed per manufacturer’s instructions (top images); then spots for EGFR, HER2, and 
HER3 were cut and removed to allow increased exposure (bottom images). Very dark spots 
in corners or middle of arrays are positive controls and not RTK spots. p-S6 in (A) is p-S6 
S235/236.  
A 
B 
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Figure 4. Genomic and proteomic analyses suggest enhanced PI3K p110α level and 
activation in LapR cells. (A) BT474 and UACC893 parental and LapR lysates were 
submitted for RPPA according to the MD Anderson RPPA Core instructions. Proteins 
increased at least 20% in LapR cells compared to parental counterparts are shown; overlap 
between proteins increased in BT474 LapR and UACC893 LapR cells is indicated by darker 
gray color. (B) Genomic DNA from BT474 parental and LapR cells was isolated and 
submitted to Otogenetics Corporation for whole-exome sequencing. Percent of WT versus 
mutant reads corresponding to p110α codon 542 are indicated.  
A 
B 
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We also performed whole-exome sequence on parental and LapR cell lines, and 
found that BT474 LapR cells possessed a heterozygous E542K activating mutation in 
PIK3CA, which encodes the p110α catalytic subunit of PI3K (Fig. 4B). This mutation 
resides in the helical domain of p110α and relieves inhibition by p85 (67, 68). The PIK3CA 
locus also had approximately double the read number in BT474 LapR cells compared to 
parental, suggesting PIK3CA may be amplified in BT474 LapR cells (data not shown). 
UACC893 LapR cells did not possess obvious cancer-associated mutations that were not 
present in parental cells; thus it was unclear whether genetic mutations induced resistance in 
these two LapR models. 
We performed western blot analysis of the PI3K pathway in parental versus LapR 
cells and found that p110α was indeed increased in BT474 LapR and UACC893 LapR cells 
compared to parental cells (Fig. 5A). Moreover, Akt phosphorylation, a prominent readout 
and effector of PI3K activation (24), was increased in these LapR cell lines under lapatinib 
treatment compared to parental cells treated with lapatinib, consistent with increased PI3K 
signaling in LapR cells. Together, these data suggest that Akt activation is enhanced in 
LapR cells through increased PI3K p110α level (BT474 and UACC893 LapR cells) and/or 
PI3K p110α activating mutation (BT474 LapR cells).  
We also found that the maintenance of Akt phosphorylation in BT474 LapR cells 
after lapatinib treatment was relatively time-independent up to 24 hours, while in parental 
cells, lapatinib inhibited Akt phosphorylation at all time points (Fig. 5B). EGFR family 
receptors (EGFR, HER2, and HER3) were not re-activated in LapR cells at any time point, 
indicating that Akt activation in LapR cells was not due to re-activation of EGFR, HER2, or 
HER3, as seen in some cases by others (69, 70). Interestingly, p-HER2 was in fact slightly  
Figure 5. PI3K p110α protein and downstream signaling
Cells were treated for 4.5 (BT474) or 4 (UACC893) hours with lapatinib or DMSO, 
followed by western blot analysis. (B) Cells were treated for indicated times with 1µM 
lapatinib, followed by western blot analysis. 
A 
B 
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 is increased in LapR cells. 
 
(A) 
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decreased in both LapR cell lines under basal conditions compared to parental cells (Fig. 
5A). This may be due to enhanced PI3K activation in LapR cells, as PI3K has been shown to 
suppress phosphorylation of HER2 and its family members (71). Alternatively, decreased p-
HER2 may be due to less dependence on HER2 and consequent tolerance of stochastic 
deletions or inactivating mutations in ERBB2 or other genes that promote HER2 
phosphorylation.   
Others have shown that feedback increase of total and phosphorylated HER3, and 
resulting increase of Akt phosphorylation, limits the efficacy of lapatinib (69, 70). We 
indeed observed some re-activation of HER3 after 12 hours of lapatinib treatment, consistent 
with the findings of other groups, but only in parental cells, and not LapR cells. This 
suggests that this feedback loop may have been exhausted by the >5 month-long treatment 
with lapatinib that was used to generated these LapR cells, and thus is not activated when 
LapR cells are treated with lapatinib. Additionally, the re-activation of HER3 in parental 
cells after 12 hours of lapatinib treatment was not sufficient to promote activation of Akt, 
contrary to the findings of others (69). These findings call into question the importance of 
the lapatinib-HER3 feedback loop.  
Activation of PI3K occurs through recruitment of PI3K p85-p110 heterodimers to 
phosphotyrosyl proteins at the cell membrane. To test whether LapR cells possessed 
enhanced PI3K membrane localization (an indicator of PI3K activation), we performed 
membrane/cytosolic fractionation on BT474 parental and LapR cells under basal and 
lapatinib-treated conditions. We found that the membrane localization of all PI3K subunits 
analyzed (p85α, p85β, p110α, and p110β, the most common PI3K subunits expressed in 
epithelial cells (62)) was inhibited after lapatinib treatment in parental cells (Fig. 6).  
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Figure 6. PI3K membrane localization is maintained in LapR cells after lapatinib treatment. 
BT474 parental and LapR cells were treated for 1.5 hours with lapatinib, followed by 
membrane/cytosolic fractionation using a sucrose-containing buffer. 30µg of membrane and 
cytosolic fractions were run by western blot. p110β is the top band in the indicated blot. 
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However, in BT474 LapR cells all of these subunits except for p85α maintained membrane 
localization after lapatinib treatment, reinforcing the idea that BT474 LapR cells possessed 
HER2-independent PI3K activation. (p85α and p85β can heterodimerize with either p110α 
or p110β and cellular p85 is thought to be in excess of p110 (25); thus membrane p110α and 
p110β may both be bound to p85β in BT474 LapR cells in this experiment.) Interestingly, 
helical p110α E545K mutations, which are thought to function similarly to E542K mutations 
(68), were previously found to promote membrane localization in defined synthetic in vitro 
systems (72). As BT474 LapR cells possess a p110α E542K helical domain mutation, it may 
be that this mutation promotes membrane localization in BT474 LapR cells, which would 
explain our results. Interestingly, p110β membrane localization is also maintained in BT474 
LapR cells after lapatinib treatment (Fig. 6). It may be that mutant PI3K p110α (and RTK-
activated p110α) recruits p110β in multimeric PI3K complexes, as indicated by some of our 
immunoprecipitation experiments in which p110β is precipitated when p110α is purified 
(data not shown).    
 
3.4. PI3K E542K-mutant cells represent the majority or founding clone in BT474 
LapR cells 
 The PI3K E542K mutation represented approximately 36% of reads in BT474 LapR 
cells, with 64% of reads being wild-type (Fig. 4B). This mutation appears to be 
heterozygous, but heterozygous mutations often appear at a near-50% ratio in a 
homogeneous population. Thus it is possible that the lower representation of E542K-mutant 
reads in BT474 LapR cells could be due to clonal heterogeneity, whereby multiple lapatinib-
resistant clones or lineages co-exist in culture, only one of which possesses a PI3K mutation. 
 29 
 
Indeed, a previous report showed that gastric cancer cells rendered resistant to a c-Met-
targeted therapy, using a system similar to ours, showed clonal heterogeneity in resistance 
mechanisms (73).  
To test whether heterogeneity might exist in our BT474 LapR cell population, we 
performed single-cell cloning of BT474 LapR cells and isolated 9 single-cell clones. We 
isolated genomic DNA from these clones as well as BT474 parental and BT474 LapR 
“pooled” cells (original BT474 LapR cells without single-cell cloning). Next, we performed 
mutation-specific qPCR of genomic DNA using primers that specifically recognize the 
E542K allele through preferential base-pairing of the 3’ nucleotide of one primer with the 
mutant allele (74), as well as total genomic PIK3CA (Fig. 7). (Mutant E542K qPCR signals 
were normalized to the qPCR signal for primers recognizing total genomic PIK3CA.) These 
data indicate that all (9 out of 9) single-cell clones possess a dramatically increased (9- to 
15-fold) E542K qPCR signal compared to BT474 parental gDNA or qPCR reaction with no 
DNA. BT474 parental gDNA and the no DNA controls induced a weak qPCR signal, likely 
through non-specific amplification of primer dimers or low-affinity genomic targets. All 
single-cell clones of BT474 LapR cells additionally possessed E542K qPCR signals similar 
to BT474 LapR pooled cells. Thus the E542K mutation was likely a founding mutation in a 
small subclone of BT474 parental cells which survived lapatinib selection and either 
represented all lapatinib-resistant cells or a lapatinib-resistant clone that came to dominate 
the lapatinib-resistant pool after extended treatment with lapatinib.  
We also used E545K-specific primers (74) as a control but found no significant 
difference between E545K qPCR signals in BT474 parental and LapR cells, as expected.  
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Figure 7. PI3K E542K mutation exists in all single-cell clones of BT474 LapR cells 
analyzed. Genomic DNA from BT474 parental, LapR, and LapR single-cell clones was 
isolated followed by qPCR using E542K- and E545K-specific primers. qPCR data was 
normalized to total genomic PIK3CA. Indicated p-value is by one-way ANOVA with 
comparison of BT474 parental with each of the BT474 LapR clones. Each of the ten p-
values (one p-value per comparison) was less than 0.01. Error bars, SEM.  
P < 0.01 
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3.5. The p110α but not p110β PI3K subunit is necessary for lapatinib resistance in 
lapatinib-resistant cell lines 
To test whether PI3K may play a causal role in lapatinib resistance, we performed 
siRNA knockdown of PI3K subunits in BT474 and UACC893 LapR cells treated with or 
without lapatinib, followed by MTT assay. (Knockdown efficiency can be seen in Fig. 8A.) 
Knockdown of p110α but not p110β (performed as a control) sensitized LapR cells to 
lapatinib (Fig. 8B). We noted, however, that p110α knockdown sensitized BT474 LapR cells 
to lapatinib much more effectively than it did for UACC893 LapR cells. We tested whether 
this may be due to less effective knockdown inhibition in UACC893 LapR cells by 
performing p110α siRNA knockdown in BT474 and UACC893 LapR cells side-by-side. We 
found that knockdown efficiency was indeed significantly better in BT474 LapR cells (Fig. 
8C), which may explain why p110α knockdown more effectively sensitized these cells to 
lapatinib. 
Because the MTT assay technically measures a specific metabolic reaction in cells 
(75) and is an indirect measure of cell number, we analyzed p110α knockdown-induced 
sensitization to lapatinib using a second assay. We fixed and stained LapR cells with a 
crystal violet/glutaraldehyde solution after treatment with p110α siRNA and/or lapatinib, 
which confirmed that knockdown of p110α, but not p110β, sensitized BT474 and UACC893 
LapR cells to lapatinib (Fig. 9). Together, these findings indicated that PI3K p110α is a key 
player in lapatinib resistance in LapR cells. 
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Figure 8. Knockdown of PI3K p110α sensitizes LapR cells to lapatinib. (A) BT474 LapR 
cells were transfected with indicated siRNAs and harvested for western blot 3 days later. (B) 
LapR cells were transfected with indicated with siRNAs, and drug or DMSO was added the 
next day. MTT assay was performed 3 days later. (C) Western blot was performed as in (A). 
Error bars, SEM. (* indicates p < 0.01 per one-way ANOVA of lapatinib-treated samples.) 
A 
B 
C 
  
 
 
 
 
Figure 9. Crystal violet stain confirms that knockdown of PI3K p110
sensitizes LapR cells to lapatinib. BT474 or UACC893 LapR cells were transfected with 
indicated siRNAs and given DMSO
stained with crystal violet/glutaraldehyde 3 days later (BT474 LapR) or re
days after original transfection and fixed and stained 
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α, but not p110
 or 1µM lapatinib the next day. Cells were fixed and 
-transfected 3 
2 days later (UACC893 LapR).
β, 
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3.6. PI3K p110α activation is sufficient to promote lapatinib resistance 
We further tested whether p110α activation is sufficent to promote lapatinib 
resistance in parental, lapatinib-sensitive cells. The p110α E545K mutation was previously 
shown to be sufficient to induce lapatinib resistance; however the E542K allele seen in our 
BT474 LapR cells was not analyzed (18). We stably expressed p110α WT, E542K, or 
H1047R. p110α H1047R was used as a positive control as this mutation has been previously 
shown to promote lapatinib resistance. All three p110α variants were expressed at 
approximately similar levels (Fig. 10A). Ectopic expression of mutant p110α E542K 
promoted lapatinib resistance in lapatinib-sensitive BT474 parental cells, whereas p110α 
WT did not (Fig. 10B). However, the expression of PI3K p110α was significantly higher 
than the endogenous level (approximately 8-10 fold when these bands are quantified using 
ImageJ); therefore it is unclear whether these mutations at endogenous levels are sufficient 
to promote lapatinib resistance. In fact, UACC893 parental cells possess a p110α H1047R 
activating mutation, although these cells are lapatinib-sensitive, though somewhat more 
resistant than BT474 parental cells (Fig. 2). UACC893 LapR cells possess increased p110α; 
thus it is possible that p110α mutations are sufficient to promote lapatinib resistance, but in a 
dose-dependent manner by which higher levels promote increased lapatinib resistance. 
In the previous experiment, vehicle-treated cell proliferation was normalized to 
100% for each cell line to account for potential variation in the number of cells plated for 
each BT474 transductant. To test whether the basal proliferation of each cell line was 
different (as a control), we performed MTT assay of each transductant at day 0 (one day 
after plating; the same day drug was added), day 2, and day 4 (Fig. 10C). We found that 
basal proliferation was minimally different between cell lines, although BT474 vector 
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Figure 10. PI3K p110α activation is sufficient to promote lapatinib resistance. (A) BT474 
parental cells were stably infected with indicated constructs followed by western blot (A) or 
MTT assay (B). MTT assay in (B) was after 4 days of DMSO or lapatinib treatment. (* 
indicates p < 0.001 by one-way ANOVA in lapatinib-treated samples.) (C) MTT assay was 
performed 0, 2, or 4 days after first measurement. (Day 0 was one day after plating.) 
Indicated p-values in (C) are by one-way ANOVA. Error bars, SEM.  
A B 
C 
Days since first measurement 
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proliferation was significantly lower than all p110α transductants (WT or mutant).  
Proliferation of BT474 cells with p110α E542K was slightly lower than cells with p110α 
WT or H1047R. 
 
3.7. p110α is upregulated through DNA amplification or post-transcriptional 
upregulation in lapatinib-resistant cell lines 
We also desired to know the mechanism by which p110α was upregulated in LapR 
cells. We performed qRT-PCR to quantify mRNA from the PIK3CA gene (which encodes 
p110α) in parental and LapR cells. Interestingly, PIK3CA mRNA was increased 2- to 3-fold 
in BT474 LapR cells but not UACC893 LapR cells compared with parental cells, indicating 
that the mechanism of upregulation is distinct in the two cell lines (Fig. 11A). We also 
analyzed PIK3CA copy number changes in LapR cells by qPCR of genomic DNA, and 
found that the PIK3CA gene was amplified approximately 2- to 3-fold in BT474 LapR cells 
(but not in UACC893 LapR cells, as expected; Fig. 11B).  
 As BT474 LapR cells possessed both mutation and amplification of PIK3CA, we 
desired to know whether the mutant allele was amplified. (The PIK3CA E542K mutation in 
BT474 LapR cells was heterozygous per our whole-exome sequencing analysis.) To do this, 
we performed qPCR on genomic DNA from BT474 parental and LapR cells using primers 
recognizing genomic PIK3CA and mutant-specific primers that preferentially base-pair with 
the mutant allele encoding p110α E542K (as in Fig. 7). We also used the BT483 breast 
cancer cell lines as a control, as this cell line is known to have an E542K mutation in p110α 
(76). This approach would allow us to see whether BT474 LapR cells had more signal from 
the E542K-specific primers compared with BT483 cells, thus allowing us to see if the 
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Figure 11. PI3K p110α increase in LapR cells is through diverse mechanisms. (A) qRT-
PCR quantifying PIK3CA mRNA level in parental and LapR cells (normalized to ACTB (β-
actin)). (B and C) qPCR of genomic DNA from indicated cell lines. E542K-specific primers 
preferentially base pair with this PIK3CA mutant allele. LINE1 was used for normalization. 
* indicates p < 0.01 by Student t test except in left part of (C), which was by one-way 
ANOVA. ** indicates no reliable measurement. Error bars, SEM. n.s., not significant. 
A 
B 
C 
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mutant allele was amplified in BT474 LapR cells. BT483 and BT474 parental cells had a 
similar copy number of total PIK3CA, indicating that BT483 cells indeed possessed non-
amplified PIK3CA E542K (Fig. 11C). However, BT474 LapR cells had more than 2-fold 
more signal from the E542K-specific primers compared with BT483 cells. (BT474 parental 
cells did not have a reliable qPCR signal using the E542K-specific primers.) These data 
indicate that the mutant p110α E542K allele is indeed amplified in BT474 LapR cells. This 
suggests that mutation alone may not be sufficient for maximal lapatinib resistance in this 
cell line, but rather that amplification may be necessary for the maximal effect. 
 
3.8. The p110α-specific PI3K inhibitor BYL719 effectively reverses lapatinib resistance 
in combination with lapatinib in vitro 
We next desired to identify a PI3K inhibitor that could overcome lapatinib 
resistance. Many PI3K inhibitors are in clinical development, most of which inhibit multiple 
PI3K isoforms (54). (p110α and p110β are expressed in epithelial cells, while p110δ and 
p110γ are expressed in many hematopoietic lineages (62).) However, pan-PI3K inhibitors 
are significantly toxic due to the importance of PI3K in a wide variety of physiological 
processes, including basic metabolic and immune functions (24, 47). Thus in cancer cases in 
which only one isoform is predominantly active, it may be preferred to target only that 
isoform in order to spare toxicities. This may allow for increased dosage, which would more 
effectively inhibit the target of interest.  
Based on this notion, several isoform-specific PI3K inhibitors have been developed, 
including p110α-specific PI3K inhibitors (77, 78). We chose the p110α-specific PI3K 
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inhibitor BYL719, produced by Novartis, as it is under clinical development and is 
reasonably well-tolerated in early clinical trials (79).  
 We first tested whether BYL719, alone or in combination with lapatinib, could 
sensitize LapR cells to lapatinib. We found that lapatinib plus BYL719 indeed sensitized 
LapR cells effectively and in a dose-dependent manner (Fig. 12A). BYL719 alone was also 
somewhat effective but not to the extent of the combination treatment. Combination 
treatment was synergistic compared to either drug alone, but only in UACC893 LapR cells 
(Fig. 12B). In BT474 LapR cells the combination was additive.   
Additionally, lapatinib plus BYL719 decreased Akt phosphorylation better than 
either drug alone (Fig. 13), likely because the two drugs blocked the two oncogenic sources 
of Akt activation in LapR cells, HER2 and mutant p110α. Consistent with previous reports 
on PI3K inhibitors (71), BYL719 alone increased phosphorylation of HER2 (Fig. 13) and 
HER3 (data not shown). However, adding lapatinib to BYL719 successfully blocked this 
increase (Fig. 13).  
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Figure 12. BYL719 overcomes lapatinib resistance in combination with lapatinib. (A) 
BT474 and UACC893 LapR cells were treated with indicated drugs for 4 days, followed by 
MTT assay. (B) Analysis of possible synergy of lapatinib plus BYL719 using the 1.0µM 
BYL719 dose from (A). P-values in (A) are by one-way ANOVA of lapatinib-treated 
samples using a post-test for linear (i.e. dose-dependent) trend. P-values in (B) are by the 
Student t-test. Error bars, SEM.  
A 
B 
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Figure 13. Lapatinib plus BYL719 effectively blocks the PI3K-Akt pathway. LapR cells 
were treated with indicated drugs for 3 hours, followed by western blot.  
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We further sought to determine whether lapatinib plus BYL719 functioned through 
proliferation inhibition, cell death, or both. To accomplish this we performed cell cycle 
analysis using flow cytometry of propidium iodide (PI) staining. PI stains DNA and thus 
cells with increased PI staining are in G2/M phase (after DNA has been replicated in S 
phase—4N peak), while cells with less DNA (2N peak) are in G1 (or G0) phase. Cells in 
between these are in S phase and in the process of replicating their DNA. Using this 
approach we found that lapatinib plus BYL719 increased the sub-G1 population left of the 
2N peak, indicating fragmentation of DNA associated with cell death, in both LapR cell 
lines (Fig. 14A). The sub-G1 population increased from less than 1% to 19.0% in BT474 
LapR cells after combination treatment, and from 11.7% in UACC893 LapR cells to 41.2% 
after combination treatment. In BT474 LapR cells neither drug alone had a significant effect 
on sub-G1 population, while in UACC893 LapR cells BYL719 alone increased the sub-G1 
population from 11.7% to 21.6%. (UACC893 LapR cells have a high level of basal cell 
death and grow slowly, which may account for the relatively high sub-G1 population under 
basal conditions.) In both LapR cell models lapatinib plus BYL719 increased the sub-G1 
population much more effectively than either drug alone. 
The combination treatment also had significant effects on the cell cycle in both LapR 
cell lines (see quantification of Fig. 14A in Fig. 14B). In BT474 LapR cells, lapatinib plus 
BYL719 increased the S phase population from 5.2% under basal conditions to 17.2%, 
while decreasing the G2/M population (4N peak) from 22.1% to 12.6%. Thus combination 
treatment apparently blocked or slowed progression from S to G2/M, or possibly killed cells 
during G2/M. Neither drug alone had this effect on the cell cycle in BT474 LapR cells. In 
UACC893 LapR cells, combination treatment decreased the G1 population from 65.3% to  
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Figure 14. Lapatinib plus BYL719 inhibits the cell cycle and induces cell death in LapR 
cells. (A) LapR cells were treated with indicated drugs for 2 days, followed by flow 
cytometric cell cycle analysis using propidium iodide staining. (B) Quantification of data 
from (A). Sub-G1 and super-G2 cells are excluded from (B).   
A 
B 
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55.8% and increased the S phase population from 8.2% to 14.9%. Thus lapatinib plus 
BYL719 appears to slow G1 entry into S phase and also prolongs S phase in UACC893 
LapR cells. Lapatinib alone and BYL719 alone moderately increased the S phase population 
in UACC893 LapR cells. 
 Together these data indicate that lapatinib plus BYL719 dramatically induce cell 
death in both LapR cell lines, while also having (apparently secondary) inhibitory effects on 
some phases of the cell cycle. In BT474 LapR cells S phase progression to G2/M is inhibited 
by combination treatment while in UACC893 LapR cells G1 entry to S as well as S phase 
progression to G2/M are inhibited.   
 
3.9. BYL719 in combination with lapatinib effectively overcomes lapatinib resistance in 
vivo 
Finally, we tested whether lapatinib plus BYL719 effectively overcomes lapatinib 
resistance in vivo. We used BT474 LapR cells orthotopically injected into the mammary fat 
pads (mfps) of nude mice, two tumors per mouse. We injected 4.5 million cells in a 1:1 
mixture of serum-free medium and growth factor-reduced Matrigel. (Ping Li helped with 
cancer cell injection.) Treatment began 8 days later. We treated mice with vehicle control, 
lapatinib, BYL719, or lapatinib plus BYL719 and measured tumor volume over time. 
Combination treatment effectively blocked the growth of LapR xenografts for over 50 days, 
and was significantly more effective than vehicle or either drug alone (Fig. 15A). 
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Figure 15. Lapatinib plus BYL719 inhibits the growth of LapR xenografts. (A) BT474 
LapR xenografts were establish in mfps of nude mice and treated with indicated drugs by 
daily oral gavage. Tumor volume was measured with calipers and normalized to day 0. * p < 
0.05 by Kruskal-Wallis one-way ANOVA of lap+BYL vs. vehicle or lapatinib; ** p  < 0.05 
for lap+BYL vs. all others; *** p < 0.0001 by Mann-Whitney of lap+BYL vs. BYL. (B) 
Mice treated in (A) were weighed on indicated days as a measure of toxicity.  
A 
B 
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As we chose BYL719 due its isoform-specific activity against PI3K p110α in order 
to reduce toxicity, we analyzed the toxicity of each treatment by analyzing the weight of 
mice treated with each regimen (Fig. 15B). (Indeed, targeted therapy combinations are often 
found to have synergistic or unexpected toxicities requiring the lowering of drug dosage 
(48).) We found that combination treatment did not significantly decrease weight over time, 
indicating that this treatment combination is well-tolerated in mice. This provides strong 
rationale for using this combination in the clinic as it is both effective and potentially safe.  
 To analyze the molecular effects of each drug, we harvested tumors from two mice 
per treatment group (four tumors total) for western blot analysis (Fig. 16). We found that 
lapatinib plus BYL719 effectively block Akt and Erk phosphorylation, and did so more 
effectively than either drug alone. This likely explains the efficacy of this drug combination. 
BYL719 alone effectively inhibited Akt phosphorylation but inhibited Erk very little, if at 
all. Lapatinib, surprisingly, did not inhibit phosphorylation of EGFR, HER2, or HER3, 
either alone or in combination with BYL719. Indeed, lapatinib plus BYL719 actually led to 
increased phosphorylation of all three of these EGFR family members. This was unexpected 
as Akt and Erk were inhibited, while their upstream activators seemed to be active (please 
see Discussion). However, others have also found that lapatinib is effective in inhibiting the 
growth of HER2+ breast cancer xenografts despite lack of inhibition of HER2 
phosphorylation (80). Additionally, in clinical trials lack of HER2 phosphorylation 
inhibition by lapatinib did not rule out clinical response (49). The reasons for this efficacy of 
lapatinib in spite of lack of target inhibition are unclear but of great interest (please see 
Discussion).     
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Figure 16. Lapatinib plus BYL719 effectively inhibits the PI3K-Akt and Erk pathways. 
BT474 LapR xenografts treated as in Fig. 12A were harvested on day 7 of treatment, 5 hours 
after the daily treatment. Four tumors (two mice) per treatment group were analyzed.  
 Figure 17. Lapatinib plus BYL719 inhibits Akt phosphorylation a
Erk phosporylation in LapR xenografts. BT474 Lap
followed by IHC for p-Erk1/2 or p
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nd heterogenously inhibits 
R xenografts were treated as in Fig. 13
-Akt T308. Staining was performed by Hai Wang.
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IHC staining (performed by Hai Wang after the author harvested the tumors) verified 
our western blot findings that Akt and Erk phosphorylation were inhibited by combination 
treatment better than either drug alone (Fig. 17). Interestingly, however, p-Erk1/2 inhibition 
by combination treatment was heterogenous by IHC, while p-Akt T308 inhibition by 
combination treatment was uniform. The reasons for this are unclear, though it is possible 
that local differences in growth factor secretion or genetic differences in tumor cells may 
cause this heterogenous p-Erk inhibition. 
 Together, these data suggest that lapatinib plus BYL719 effectively reverses 
lapatinib-resistant tumor growth at least partly through inhibition of the Akt and Erk 
pathways. Although we expected inhibition of Akt by BYL719, inhibition of Erk was 
unexpected. Interestingly, after we completed this study another group also found evidence 
that BYL719 may inhibit Erk phosphorylation in some settings (81). The reasons for 
synergistic (and heterogeneous) inhibition of Erk phosphorylation by lapatinib plus BYL719 
remain unclear but are of interest for future study.   
 
3.10. Summary of chapter 3 
In summary, we have found that lapatinib-resistant cells possess enhanced PI3K 
p110α expression and activation. This appears to promote or be necessary for lapatinib 
resistance, as genetic or pharmacological inhibition of p110α reverses lapatinib resistance in 
vitro and in vivo. These data strongly suggest the use of lapatinib combined with p110α-
specific PI3K inhibitors to overcome lapatinib resistance in patients with HER2+ breast 
cancer. 
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Chapter 4. Lapatinib-resistant cells are dependent on PI3K-independent mTOR 
activation 
 
4.1. Introduction 
 In Chapter 3 we discussed two of our three lapatinib resistance models and indicated 
that PI3K was necessary for lapatinib resistance in those models. In this chapter we discuss a 
PI3K-independent mechanism of mTOR activation that appears to be necessary for lapatinib 
resistance in our third model, the AU565 lapatinib-resistant cell line. 
 
4.2. AU565 lapatinib-resistant cells possess PI3K-independent mTOR activation 
 As discussed previously, AU565 LapR cells appeared to have a PI3K-independent 
mechanism of lapatinib resistance and were thus studied separately from BT474 and 
UACC893 LapR cell lines. As with other lapatinib-resistant cell lines, we found that AU565 
LapR cells were highly resistant to lapatinib compared to parental cells (Fig. 18).  
 AU565 LapR cells, as with BT474 LapR cells, did not possess activation of 
alternative RTKs that might potentially promote lapatinib resistance (Fig. 19A). However, 
AU565 LapR cells possessed aberrant activation of a downstream component of the PI3K 
pathway, namely mTOR. Indeed, in AU565 parental cells lapatinib strongly inhibited 
phosphorylation of the ribosomal protein S6, a downstream effector of mTOR which, when 
phosphorylated, leads to increased protein translation (30, 82). However, in AU565 LapR 
cells, lapatinib inhibited S6 phosphorylation only slightly (Fig. 19A, B). 
 Interestingly, HER2 phosphorylation was significantly decreased in AU565 LapR 
cells compared with parental cells under basal conditions, and this correlated with decreased 
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basal p-Akt (Fig. 19B), which could indeed potentially result from decreased 
phosphorylation of HER2 family members. This decreased HER2 phosphorylation could be 
due to increased activation of mTOR or other pathways in AU565 LapR cells that can 
potentially inhibit upstream receptor phosphorylation (83), and is consistent with (though 
more dramatic than) what we found in our previous two LapR models (Fig. 5A).   
Additionally, AU565 LapR cells maintained phosphorylation of the mTOR downstream 
target 4E-BP1 after lapatinib treatment, whereas the highest molecular weight form (the 
most phosphorylated form) was inhibited in parental cells after lapatinib treatment (Fig. 20). 
(4E-BP1 binds to the elongation factor eIF4E and inhibits its translation-promoting activity 
(30, 84). 4E-BP1 phosphorylation by mTOR inhibits this function to allow eIF4E’s 
translation-promoting functions.) 
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Figure 18. AU565 LapR cells are markedly lapatinib-resistant. AU565 parental and LapR 
cell lines were treated with indicated concentrations of lapatinib for 4 days, followed by 
MTT assay. All MTT assay readings were normalized to DMSO control (=100%).  
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Figure 19. AU565 LapR cells possess Akt-independent S6 phosphorylation. (A) Lysates 
from AU565 parental or LapR cells (treated with 1µM lapatinib or DMSO for 2 hours) were 
added to Cell Signaling PathScan RTK Signaling Antibody arrays per manufacturer's 
instructions and visualized by chemiluminescence. (B) AU565 parental and LapR cells were 
treated with 1µM lapatinib for indicate times and harvested for western blot.  
A 
B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. AU565 LapR cells
treatment compared to parental cells
with lapatinib followed by western blot.
before harvest on day of harvest.) 
from the same samples.   
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 maintain 4E-BP1 hyperphosphorylation under lapatinib 
. AU565 parental and LapR cells were treated for
 (Fresh drug in fresh medium was given 4 hours 
Loading control is the same as in Fig. 26B as this wa
 2 days 
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4.3. AU565 lapatinib-resistant cells are sensitive to mTOR but not PI3K inhibition 
Moreover, AU565 LapR cells were sensitive to the dual PI3K/mTOR BEZ235 but 
not to the PI3K inhibitor GDC0941 (Fig. 21A). In contrast, AU565 parental cells were 
highly sensitive to both. These data reinforce the notion that AU565 LapR cells possess a 
PI3K-independent resistance mechanism, as they have lost PI3K dependence. Additionally, 
the mTORC1 inhibitor temsirolimus (85) effectively overcame lapatinib resistance in 
AU565 LapR cells (Fig. 21B), but not as well as BEZ235, which blocks both mTORC1 and 
mTORC2 by blocking the catalytic activity of the mTOR kinase (86). (mTORC1 is an 
mTOR-containing complex of proteins that promotes S6 and 4E-BP1 phosphorylation, 
among others, while mTORC2 regulates Akt, SGK, and other proteins (30).)  
To test whether S6 phosphorylation (indicative of mTOR activation) was indeed 
PI3K-independent, we treated AU565 LapR and parental cells with the PI3K inhibitor 
GDC0941 and analyzed S6 phosphorylation. S6 phosphorylation was indeed PI3K-
independent in AU565 LapR cells but not in AU565 parental cells (Fig. 21C), consistent 
with resistance to GDC0941 in LapR cells and decrease of p-Akt in AU565 LapR cells. We 
also analyzed whether S6 phosphorylation in AU565 LapR cells was independent of Akt, a 
downstream target of PI3K. Unexpectedly, however, the allosteric Akt inhibitor MK2206 
did not inhibit S6 phosphorylation even in AU565 parental cells (Fig. 21C). This suggests 
that HER2 and PI3K may induce S6 phosphorylation independent of Akt in AU565 parental 
cells, as lapatinib and GDC0941, but not MK2206, can inhibit p-S6 in parental cells. In 
AU565 LapR cells, S6 phosphorylation, as expected, is independent of both PI3K and Akt. 
Together, these data indicate that AU565 LapR cells have lost dependence on PI3K 
but not mTOR, and that mTOR activation is PI3K-independent in these cells. 
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Figure 21. AU565 LapR cells have lost dependence on PI3K but not mTOR. (A) AU565 
parental and LapR cells were treated with GDC0941 or BEZ235 for 4 days, followed by 
MTT assay. (B) AU565 LapR cells were treated with the mTORC1 inhibitor temsirolimus 
or BEZ235 for 5 days, followed by MTT assay. P-values by Student t-test.  (C) After 4.5 
hours of GDC0941 (1µM) or MK2206 (0.5µM) treatment, cells were harvested for western. 
A 
B C 
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4.4. S6 phosphorylation in AU565 lapatinib-resistant cells is Rheb- and mTOR-
dependent but independent of known upstream Rheb activators 
As mentioned previously, AU565 LapR cells do not have activation of alternative 
RTKs compared to parental cells, per our phospho-RTK array (Fig. 19A). We therefore 
tested whether known modulators of the mTOR pathway are differentially activated in 
AU565 parental versus LapR cells. We tested the activation and/or total level of a variety of 
known mTOR modulators, including Akt, AMPK, Erk, PRAS40, Rheb, TSC2 (Fig. 22), 
GSK3β, and IKK (30). However, none of these pathways or proteins were differentially 
expressed or activated in AU565 parental versus LapR cells (Fig. 22; data not shown for 
GSK3β and IKK). (For this and the next few experiments we used a representative single-
cell clone of AU565 LapR cells to avoid the potential clonal heterogeneity seen by others 
using a similar drug resistance models (73), and is indicated as “AU565 LapR*”.) 
 Rheb is immediately upstream of mTORC1 and is a growth factor-dependent 
activator of mTORC1. Therefore we tested whether mTOR activation in AU565 LapR cells 
was Rheb-dependent. We found that siRNA knockdown of Rheb in AU565 LapR cells 
eliminated S6 phosphorylation to a similar degree as mTOR knockdown (which served as a 
positive control; see Fig. 23A and also Fig. 23B for knockdown efficiency). 
Interestingly, however, Rheb knockdown only inhibited S6 phosphorylation under 
lapatinib-treated conditions in AU565 LapR cells but not under basal conditions in AU565 
LapR or parental cells (Fig. 23A). The same phenomenon was seen with mTOR knockdown. 
Two possible explanations for this phenomenon are: (1) incomplete knockdown of Rheb or 
mTOR allows continued signaling through these pathways as HER2 strongly activates these 
pathways under basal conditions, or (2) basal S6 phosphorylation is independent of the  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Known mTOR activation mechanisms are not 
AU565 LapR cells. AU565 parental and LapR cells were treated for 
lapatinib or vehicle control, followed by western blot. Cell Signaling positive control
was used as p-IKK positive control (from cells treated with TNF
that a single-cell clones of AU565 LapR cells was used
here were from the same lysate, and the same 
column for ease of loading control comparison. 
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Figure 23. PI3K-independent S6 phosphorylation in AU565 LapR cells is Rheb
mTOR-dependent. (A) Indicated cell lines were treated with indicated siRNAs for 3 days, 
followed by treatment with lapatinib (1
(B) AU565 LapR cells were treated with indicated siRNAs for 3 days, followed by western 
blot. (C) Indicated cell lines were treated with indicated 
western blot. Asterisk (*) indicates that a single
A 
C 
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mTOR pathway. To potentially answer this question, we treated AU565 LapR cells with the 
mTORC1 inhibitor RAD001 and found that RAD001, alone or combined with lapatinib, 
effectively inhibited S6 phosphorylation (Fig. 23C). 
This suggests that possibility (1) above is correct; that is, that incomplete knockdown 
of Rheb or mTOR allowed continued HER2-induced S6 phosphorylation under basal 
conditions. Indeed, we were only able to achieve a 50-60% decrease in Rheb protein level 
using siRNA. Although off-target effects of RAD001 could potentially result in S6 
phosphorylation inhibition through inhibition of proteins other than mTOR, this is less likely 
compared to most kinase inhibitors, which are more promiscuous due to binding to a semi-
conserved ATP-binding pocket present in all kinases (87). RAD001 is an allosteric, not an 
ATP-competitive, inhibitor of mTOR and thus off-target effects on other kinases are less 
likely.   
Based on these findings we conclude that AU565 LapR cells may possess Rheb-
dependent, but HER2/RTK-independent, activation of mTOR. The upstream activator of 
Rheb in this system is unclear and independent of the canonical Rheb-activating pathways. 
Treatment with mTOR inhibitors in combination with lapatinib inhibits S6 phosphorylation 
and sensitizes AU565 LapR cells to lapatinib. 
 
4.5. Mutational analysis of AU565 parental and lapatinib-resistant cell lines suggests 
that multiple subtle mutations may play a role in lapatinib resistance 
To identify potential mutations involved in lapatinib resistance and/or mTOR 
activation in AU565 LapR cells, we performed whole-exome sequencing of parental and 
LapR cells. We did not identify any known cancer-associated point mutations in AU565 
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LapR cells that are not present in parental cells (data not shown). However, we observed 
significant copy-number alterations in AU565 LapR cells compared to parental cells, 
sometimes in large regions (Fig. 24). We represented these findings by taking the ratio of 
sequencing read counts in LapR versus parental cells (LapR / parental) such that regions 
with equal copy number have a ratio of 1.0, regions amplified in LapR cells are >1.0, and 
regions lost in LapR cells are <1.0. Fig. 24 represents these ratios for each exon from 
chromosome 1 to chromosome X. We analyzed whether genes in the mTOR pathway are 
amplified or deleted in AU565 LapR cells compared to parental cells. We found that one 
copy of the proposed Rheb/mTOR inhibitor FKBP38 (FKBP8 gene) was deleted in LapR 
cells compared with parental cells (see arrow, Fig. 24) as the LapR / parental copy ratio was 
~0.5 in and around the FKBP38 gene. FKBP38 was previously reported to bind to and 
inhibit Rheb’s mTOR-promoting function (88).  
To test whether FKBP38 was indeed decreased in LapR cells compared to parental 
cells, we performed western blot for FKBP38. Our findings verify that FKBP38 is indeed 
decreased in AU565 LapR cells (Fig. 25A). We also tested whether FKBP38 loss may be a 
founding mutation in lapatinib resistance (rather than a later event due to long-term culture 
in lapatinib) by testing FKBP38 expression in an earlier AU565 LapR culture that had only 
been cultured in lapatinib for 4 months (rather than >6 months in the other AU565 
LapR cells presented here) yet were still highly lapatinib-resistant (data not shown). This 
verified that FKBP38 was indeed decreased in these earlier-passage LapR cells as well (Fig. 
25A). 
To test whether FKBP38 loss may be sufficient to promote lapatinib resistance and 
may enhance mTOR activation, we knocked down FKBP38 in AU565 parental cells by  
  
 
 
 
 
 
Figure 24. Copy-number variations in AU565 LapR cells compared to parental cells. 
Whole-exome sequencing was performed on AU565 parental and LapR 
cells and copy number was inferred based on read number for each exon using a 20
window. AU565 parental and LapR cell read counts were normalized, after which the ratio 
for each normalized read count for each exon (AU565 LapR / AU565 pare
calculated. Thus ratios of >1.0 indicate amplification in AU565 LapR cells while <1.0 
indicates deletion in AU565 LapR cells. 1.0 indicates no change in parental versus LapR 
cells. The approximate locations of single
(protein name FKBP38) are indicated.  
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Figure 25. FKBP38 and Rb1 loss are not sufficient to promote lapatinib resistance. (A) 
Indicated cell lines were analyzed by 
LapR cells. (B) Western blot showing knockdown efficiency of Rb1 and FKBP38 shRNAs 
in AU565 parental cells. Hsp90 was used as
FKBP38 siRNAs. (D) MTT assay was performed on cells from (B) after 4 days of treatme
with DMSO or 1µM lapatinib. (E) AU565 parental cells were transfected with same siRNAs 
indicated in (C) and 3 days post
5 hours, followed by western blot.
A B 
D 
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shRNA or siRNA (knockdown efficiency shown in Fig 25B, C). We found that FKBP38 
knockdown in AU565 parental cells was not sufficient to promote lapatinib resistance (Fig. 
25D). Additionally, FKBP38 knockdown did not enhance S6 phosphorylation, either under 
basal or lapatinib-treated conditions (Fig. 25E). Thus it may be that the role of FKBP38 in 
mTOR activation is cell-line specific (see Discussion and indicated references which 
question the role of FKBP38 in mTOR activation (89, 90)).   
We also noted a 2-fold amplification of the mTORC2-associated gene PRR5 in 
AU565 LapR cells compared to parental. PRR5 encodes the Protor1 protein, which 
promotes mTORC2 activation (30, 91). However, this ~2-fold copy-number increase was 
associated with increased copy of the entire chromosome on which PRR5 resides 
(chromosome 22), which makes the importance of this amplification unclear (see large 
amplified region at the right end of Fig. 24). Additionally, the mTORC2 activation marker 
p-Akt S473 (30) is actually decreased in AU565 LapR cells (Fig. 21C), which further 
indicates that this amplification may not necessarily play a role in lapatinib resistance. 
We also analyzed whether ~500 other cancer-associated genes (from the Sanger 
Cancer Gene Census) experienced copy number changes in AU565 LapR cells compared to 
parental. We found that the tumor suppressor genes RB1 and ARID1A, both of which are 
important for breast cancer suppression (92, 93), were also hemizygously deleted (single-
copy loss) in LapR cells compared to parental (Fig. 24). However, Rb1 knockdown by 
shRNA in AU565 parental cells was not sufficient to promote lapatinib resistance (Fig. 25B, 
D). (We used phospho-Rb as an indicator of knockdown efficiency because Rb1 can be 
phosphorylated a large number of residues (94) and antibodies recognizing total or non-
phosphorylated Rb1 are relatively difficult to identify.) Additionally, ARID1A loss was 
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likely a late event in AU565 LapR evolution as our AU565 LapR early culture (after only 4 
months of lapatinib selection) did not have any decrease in ARID1A protein expression 
(data not shown). Thus it is unlikely that ARID1A loss was an initial essential event 
promoting lapatinib resistance.   
Together, these data indicate that, although several potential tumor suppressors are 
lost in AU565 LapR cells, none of them alone appears to be playing a direct role in lapatinib 
resistance. However, it is possible that multiple copy number losses or gains may collaborate 
in subtle ways to additively or synergistically promote lapatinib resistance. Indeed, we saw 
large numbers of copy gains and losses in AU565 LapR cells. The Elledge group has found 
that certain chromosomal regions have a “net tumor-suppressive” function while others have 
a “net oncogenic” function through interactions of multiple genes that may subtly affect 
cancer growth cumulatively (95). This may indeed be what has happened in AU565 LapR 
cells in relation to their mechanism of lapatinib resistance.  
 
4.6. Multiple inhibitors of apoptosis (IAPs) are increased in AU565 lapatinib-resistant 
cells and mTOR inhibition reverses IAP expression  
In the absence of the activation of known mTOR-activating pathways, we tested 
other potential mechanisms of resistance downstream of mTOR in order to identify possible 
drug targets. We first analyzed whether mTOR activation in AU565 LapR cells may inhibit 
apoptosis by testing whether cytochrome C release was inhibited in AU565 LapR cells 
compared to parental cells. (Cytochrome C is a mitochondrial protein which, when released 
from the mitochondria into the cytosol through pro-apoptotic signals, activates caspases to 
promote cleavage of cellular proteins and the apoptotic process in general (96).) To analyze 
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cytochrome C release from the mitochondria, we analyzed the cytosolic fraction of AU565 
parental and LapR cells treated with or without lapatinib using sucrose fractionation to 
remove mitochondria (and nuclear) fractions. Cytochrome C was released into the cytosol of 
AU565 parental cells after 2 days of treatment with lapatinib (Fig. 26A). Surprisingly, 
however, AU565 LapR cells possessed constitutive cytosolic cytochrome C, even under 
basal conditions, which would be expected to induce apoptosis.  
This suggests that AU565 LapR cells have dysregulated Bcl-2 family signaling 
compared to parental cells, as Bcl-2 family proteins normally control the release of 
cytochrome C into the cytosol to determine apoptotic fate (96). Constitutive cytochrome C 
localization in AU565 LapR cells may be due to decreased phosphorylation of Akt in 
AU565 LapR cells. Akt phosphorylates and inhibits activation of the pro-apoptotic Bcl-2 
family member Bad, thus inhibiting apoptosis (97). Thus loss of Akt phosphorylation in 
AU565 LapR cells would theoretically lead to increased Bad activation and release of 
cytochrome C from mitochondria, as seen in AU565 LapR cells.  
 Further, the inhibitors of apoptosis proteins (IAPs) are a class of proteins capable of 
blocking apoptosis downstream (e.g. in spite of) of cytochrome C release into the cytosol by 
blocking caspase activation through various means (98). We tested the levels of several 
IAPs from Cell Signaling’s IAP antibody sampler kit. We found that the IAP survivin was 
maintained in AU565 LapR cells treated with lapatinib, while it decreased after lapatinib 
treatment in AU565 parental cells (Fig. 26B). Moreover, c-IAP-2 was increased under basal 
and lapatinib-treated conditions in AU565 LapR cells. The mTOR kinase inhibitor 
AZD8055 (which inhibits both mTORC1 and mTORC2) effectively decreased the 
expression of survivin and c-IAP-2, especially when combined with lapatinib (Fig. 26B). 
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This indicates that upregulation of these IAPs (survivin and c-IAP-2) may be mTOR-
dependent and suggests a possible mechanism by which mTOR inhibitors sensitize AU565 
LapR cells to lapatinib. That is, mTOR inhibitors may induce apoptosis by allowing 
cytosolic cytochrome C to fully activate caspases through decreasing the expression of IAPs 
that normally inhibit caspase activation in AU565 LapR cells. Expression of the IAPs c-
IAP-1 and XIAP was not dramatically upregulated in AU565 LapR cells. XIAP was slightly 
increased in LapR cells and this increase was slightly inhibited by AZD8055 (Fig. 26B), but 
it appears that c-IAP-2 and survivin may play a more important role than XIAP.  
 To test whether survivin was necessary for lapatinib resistance, we knocked down 
survivin in AU565 LapR cells and tested whether this sensitized the cells to lapatinib. 
However, we did not see any sensitization effect (data not shown). This suggests that 
multiple IAPs, such as c-IAP-2, may play a role in lapatinib resistance. There are several 
other members of this family we did not test as well, and so it is impossible to rule out a 
cooperative effect of multiple IAPs on lapatinib resistance. Measuring and knocking down 
all such IAPs is at once is a technically difficult challenge and we did not pursue this further 
at this time.  
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Figure 26. mTOR activation promotes IAP expression in AU565 LapR cells. (A) Cells were 
treated with DMSO or 1µM lapatinib for two days and harvested for fractionation. Sucrose 
fractionation was performed to remove the mitochondrial/nuclear fractions and the cytosolic 
and membrane fractions were analyzed by western blot. Whole cell extract was also 
analyzed as a control. (B) Western blot of AU565 parental and LapR cells treated with 
indicated drugs for 2 days. Lapatinib was given at 1µM and AZD8055 at 0.5µM. 
A 
B 
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4.7. Hsp90 inhibition reverses IAP expression and inhibits growth of AU565 lapatinib-
resistant cells 
 Due to the toxicities of mTOR inhibitors (57, 58), we tested other strategies to 
reverse lapatinib resistance in AU565 LapR cells. Some IAPs are known or thought to be 
stabilized by Hsp90 (99, 100), a molecular chaperone which promotes the stability of some 
proteins (“clients”) by promoting correct folding after protein translation (101). We 
reasoned that inhibition of expression of some or all IAPs in AU565 LapR cells with Hsp90 
inhibitors, which are clinically applicable (102, 103), may allow cytosolic cytochrome C to 
initiate the apoptotic cascade by eliminating IAP-induced inhibition of caspase activation.  
 To test whether IAP expression can be reversed by Hsp90 blockade, we treated 
AU565 LapR cells with the Hsp90 inhibitor 17-AAG, which has shown activity in clinical 
trials for HER2+ breast cancer (102, 103). 17-AAG blocked expression of c-IAP-2 and also 
c-IAP-1, though unexpectedly it did not block expression of survivin (Fig. 27A), one of the 
two IAPs increased in LapR cells and a previously reported Hsp90 client (99). HER2, as 
previously reported, was also inhibited by 17-AAG (104, 105). 17-AAG treatment also 
inhibited AU565 LapR cell growth to a degree similar to mTOR inhibitors (Fig. 27B). 17-
AAG was not additive when combined with lapatinib, suggesting that 17-AAG alone may 
be sufficient. Moreover, AU565 parental and LapR cell growth were inhibited to a similar 
degree by 17-AAG (Fig. 27C). (Although there is a slight separation between the two 
curves, this is because basal proliferation of AU565 LapR cells is slower, making the 
baseline lower. Absolute proliferation at all doses shown was essentially identical in parental 
and LapR cells (data not shown).) Sensitivity of both parental and LapR cells may be 
because AU565 parental cells are HER2-dependent and thus sensitive to Hsp90 inhibition, 
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which causes HER2 loss, while AU565 LapR cells may be sensitive to 17-AAG due to 
dependence on IAPs. 
 Together, these data suggest an alternative to potentially toxic mTOR kinase 
inhibitors for lapatinib-resistant, mTOR-dependent HER2+ breast cancer. Enhanced IAP 
expression may be a biomarker for sensitivity to 17-AAG in HER2+ breast cancer, which 
merits further study.   
  
4.8. Summary of chapter 4 
To summarize, we found that PI3K-independent activation of mTOR may play a role 
in lapatinib resistance. Lapatinib in combination with mTOR or Hsp90 inhibitors effectively 
reverses lapatinib resistance. The mechanism of PI3K-independent mTOR activation 
remains unclear, but IAPs downstream of mTOR may be required for lapatinib resistance. It 
appears that AU565 LapR cells have dysregulated signaling among the Bcl-2 family 
proteins, leading to constitutive localization of cytochrome C in the cytosol, possibly due to 
decreased Akt signaling, which inhibits apoptosis through interactions with the Bcl-2 family. 
Thus AU565 LapR cells may have essentially “given up” on preventing apoptosis upstream 
of cytochrome C, but may have efficiently rewired their IAP signaling to block caspase 
activation downstream of mitochondrial cytochrome C release. A possible model of the 
rewiring of apoptotic signaling in AU565 LapR cells is shown in Fig. 28.  
A summary of the PI3K-independent lapatinib resistance signaling mechanisms in 
this chapter, as well as the PI3K-dependent mechanisms in chapter 3, is represented in 
Figure 29. Together, these data strongly suggest the use of lapatinib in combination with 
PI3K, mTOR, or Hsp90 inhibitors for lapatinib-resistant HER2+ breast cancer. 
  
 
 
Figure 27. Hsp90 inhibition reverses expression of some IAPs and reverses lapatinib 
resistance in AU565 LapR cells. (A) Cells were treated with 1µM lapatinib or Hsp90 
inhibitor 17-AAG (1µM) for two days followed by western blot. (B and C) Indicated cell 
lines were treated for 3 days with indicated drugs, followed by MTT assay. In (B) p < 0.01 
by one-way ANOVA (vehicle vs. all other groups). In (C) proliferation for each cell line was 
normalized to that cell line’s vehicle proliferation (=100%).
A 
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Figure 28. Model of changes in apoptotic signaling in AU565 LapR cells. AU565 parental 
cells (top) suppress apoptosis by inhibiting cytochrome C release
LapR cells (bottom) may suppress apoptotic signaling through
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 from mitochondria, while 
 IAPs. 
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Figure 29. Model of mechanisms of lapatinib resistance identified. Top shows that the 
PI3K-mTOR axis is driven primarily by HER2 in lapatinib-sensitive breast cancers, while 
bottom shows that lapatinib-resistant breast cancers have multiple inputs to PI3K-mTOR. 
OR 
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Chapter 5. Discussion 
 HER2-independent activation of PI3K and mTOR is a well-known mechanism of 
resistance to anti-HER2 therapy (4, 10, 28). Here we report additional potential mechanisms 
by which PI3K and mTOR can be activated to promote resistance to the HER2 kinase 
inhibitor lapatinib and combination therapies that may reverse lapatinib resistance in 
patients. 
 Confirming our findings regarding lapatinib resistance mechanisms in patient tissues 
is highly desirable. A recent publication from our laboratory found that resistance to 
neoadjuvant treatment with lapatinib monotherapy in HER2+ breast cancer patients was 
associated with increased mTOR activation by gene set enrichment analysis (106), which 
appears to corroborate with our discovery of enhanced mTOR activation in AU565 LapR 
cells. It has been previously reported that PI3K mutations are associated with lapatinib 
resistance in HER2+ breast cancer patients (19); however, enhanced PI3K p110α protein 
level in lapatinib-resistant patient tissues has not been analyzed. We compared p110α 
protein levels in BT474 parental vs. BT474 LapR xenografts by IHC to determine whether 
the ~2-fold increase in p110α in BT474 LapR cells might be observable by IHC in clinical 
specimens (data not shown). However, no difference was apparent by IHC, indicating that 
IHC might not currently be sufficiently sensitive to identify this change in clinical 
specimens. Additionally, tumor tissue from lapatinib-treated patients is difficult to obtain 
and few, if any, such archival specimens are present at MD Anderson Cancer Center. 
However, concurrent mutation and amplification of PIK3CA has been observed in clinical 
breast cancer specimens (107), suggesting that increase in p110α with concurrent mutation 
may be clinically relevant. 
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 BYL719 in combination with HER2 targeted therapy is already being tested by other 
groups in clinical trials for patients with HER2+ breast cancer. We expect the greatest 
efficacy for these drugs, as with lapatinib alone, will be in the neoadjuvant setting where 
genetic heterogeneity and disease aggressiveness is at its lowest (relative to later metastatic 
disease).  
 Interestingly, shortly after we published our findings regarding mutant PI3K in 
acquired lapatinib resistance, another study reported similar results (108). The authors 
generated BT474 lapatinib-resistant cells using an approach very similar to ours, and, 
strikingly, also identified a PI3K p110α E542K mutation in their BT474 lapatinib-resistant 
cells that was not present in parental cells. This raises the interesting question as to whether 
the E542K subclone existed in the original HER2+ tumor from which the BT474 cell line 
was derived, as that sub-clone is apparently now present in widely divergent populations of 
BT474 cells from our lab and in Tennessee, where the authors of this work performed their 
research. This offers further indication that mutant drug-resistant sub-clones frequently pre-
exist in drug-sensitive tumors and are selected for positively after drug treatment.  
The authors of the other lapatinib resistance study also used a PI3K inhibitor in 
combination with lapatinib and found that this reversed lapatinib resistance. However, they 
used BKM120, a pan-PI3K inhibitor, which as we have noted may be less ideal than 
BYL719 due potentially to more dose-limiting toxicities. However, acquired resistance to 
p110α-specific PI3K inhibitors like BYL719 could potentially be through enhanced p110β 
activity, which pan-PI3K inhibitors would theoretically target. It is unclear whether 
sequential p110α-specific PI3K inhibition followed by pan-PI3K inhibition may be superior 
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to starting with pan-PI3K inhibitors, but as clinical trials further elucidate the relative 
toxicities of these two classes of drugs the answer may become clearer.    
As noted, lapatinib plus BYL719 more effectively inhibited Erk phosphorylation 
than either drug alone in vivo, and this correlated with highly effectively tumor inhibition. 
Additionally, this combination did not decrease phosphorylation of HER2 and its family 
members, but in fact paradoxically increased phosphorylation of EGFR, HER2, and HER3. 
This is contradictory to the currently understood model of RTK signaling wherein receptor 
phosphorylation leads to increased activation of the PI3K-Akt and MAPK pathways (109). It 
may be that other protein modulators of the pathway can block activation of these pathways 
even when RTKs are phosphorylated. Alternatively, it may be that the kinase inhibitors used 
have uncharacterized off-target effects (87). Finally, it is possible that the drugs used induce 
conformational changes in the proteins targeted that preclude binding of phospho-RTKs to 
the proteins that recognized these phosphotyrosines. For example, lapatinib may stabilize 
HER2-HER2 and/or HER2-HER3 dimers such that close interactions between the C-
terminal tails of the dimers sterically hinder the binding of PI3K or MAPK-activating 
adapters to those phosphotyrosines. As mentioned, others have shown that lapatinib can 
inhibit xenograft growth in vivo, notwithstanding lack of inhibition of HER2 
phosphorylation (80). Maintenance of phosphorylation combined with inability of PI3K and 
other proteins to bind to those phosphotyrosines offers a neat and testable hypothesis that 
deserves future study, as this may further elucidate the mechanisms of RTK activation. 
Additionally, understanding why this phenom enon is observed in vivo but not in vitro 
may also provide valuable insight.    
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Further advances to decrease the toxicities of PI3K inhibitors are needed. Although 
we observed that lapatinib plus BYL719 did not induce weight loss in mice, BYL719 has 
been shown to induce diabetes-like symptoms (hyperglycemia) in patients treated with 
BYL719 monotherapy (79). Thus it may be that lapatinib plus BYL719 will have significant 
(or even synergistic) toxicities. Although BYL719 represents a significant advance through 
targeting a specific PI3K isoform (a challenging pharmaceutical feat), mutant-specific PI3K 
inhibitors represent the next exciting advance in PI3K targeted therapy. The PI3K p110α 
subunit is mutationally activated in some 10% of all cancers and in 30-35% of breast cancers 
(estimates are based on TCGA data accessed from cBioPortal). Mutant-specific PI3K 
inhibitors thus have great potential to treat a large number of cancer patients while in theory 
possessing no toxic side-effects, as they would ideally not target wild-type PI3K or any 
other cellular proteins.  
Mutant-specific PI3K inhibitor pharmaceutical development should begin with the 
helical domain mutations. Kinase domain mutations (such as H1047R) represent some 30-
40% of PI3K mutations, while helical domain mutations represent a similar percentage ((55) 
and estimates from TCGA data accessed from cBioPortal). However, the helical domain 
mutations are perhaps better understood. The p110α helical domain mutations, including the 
common E545K and E542K mutations, are thought to disrupt kinase-inhibitory interactions 
between p85 and p110, with an effect similar to that of p85 binding to phosphorylated RTKs 
(67, 68). Mutant-specific drugs that bind specifically to p110α E542K or E545K (and not 
wild-type p110α) and that restore the p85-p110 interaction would be ideal on two fronts: 
maximal efficacy and minimal toxicity. This would allow such a drug to be combined with 
other targeted therapies without the worry of synergistic or additive toxicities. This is 
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essential as PI3K mutations are often found in association with other oncogenes (110, 111) 
and targeted therapy combinations frequently result in unexpected toxicity (17, 48). Further 
basic studies to understand the function of the H1047R mutation are necessary for the 
development of mutant-specific drugs targeting this site, though kinase cleft-binding drugs 
that can be engineered to be arginine-reactive and not histidine-reactive could potentially 
bind to the mutant arginine at H1047R and disrupt its function. This concept has recently 
been used to develop a mutant-specific inhibitor of K-Ras G12C which specifically binds to 
the mutant cysteine and does not affect the wild-type protein (112).  
Because we found that helical domain mutations promoted lapatinib resistance, we 
attempted the development of helical mutant-specific PI3K inhibitors. Our collaborators Dr. 
Shuxing Zhang and his student Lu Chen performed modeling of the p85-p110α E545K 
interaction (based on a wild-type crystal structure of parts of the dimer) and identified 50 
potential small-molecule compounds that might bind specifically to this mutant (and not 
wild-type) complex and restore p85’s inhibitory interactions with p110α. We developed an 
assay to test whether these compounds inhibited p110α E545K-driven cell growth without 
affecting p110α H1047R-driven cell growth (as a negative control). Unfortunately, however, 
we did not find any of these compounds to specifically inhibit p110α E545K.  
While doing these experiments, a study was published that indicated that p110α 
E545K functioned partly through a gain-of-function interaction with IRS-1 (113). Treatment 
of p110α E545K-driven cancer cells with a stapled peptide including and surrounding the 
p110α E545K amino acid titrated away IRS-1 and thus specifically inhibited mutant p110α 
E545K but not wild-type p110α. This thus stapled peptide may represent a lead for the 
development of mutant-specific PI3K inhibitors. Their findings may also explain why our 
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mutant-specific PI3K inhibitor development did not work: it may be that IRS-1 binding to 
mutant PI3K may have interfered with small molecules designed to restore the p85-p110α 
interaction. Stapled peptides against other helical domain mutations, such as E542K, may 
also be developed using a similar approach.    
Growth of our AU565 LapR model of mTOR-associated lapatinib resistance was 
effectively inhibited by lapatinib plus the mTOR kinase inhibitor AZD8055. However, as 
mentioned, mTOR kinase inhibitors are likely to be significantly toxic and it may be 
impossible to use current mTOR inhibitors at sufficient dosage to inhibit the intended target 
in cancer cells. Thus identification of the mTOR upstream activator is desirable (though 
difficult). Another group previously reported a lapatinib resistance model similar to ours in 
which PI3K-independent mTOR activation fueled cell proliferation (114). These authors 
were also perplexed as to the upstream activator of mTOR, and it may be that our AU565 
LapR model possessess novel mTOR signaling mechanisms worthy of further study.   
Our incidental finding that FKBP38 knockdown does not promote mTOR activation 
adds to a growing body of literature that refutes the role of FKBP38 in mTOR activation 
(89, 90). A 2007 study indicated that FKBP38 acts as an endogenous inhibitor of Rheb and 
thus acts as an inhibitor of mTOR (88). Because of our observation of increased mTOR 
activation in AU565 LapR cells as well as hemizygous loss of the gene encoding FKBP38, 
we hypothesized that FKBP38 loss may have promoted the mTOR activation in AU565 
LapR cells; however, we found that FKBP38 knockdown was insufficient to promote mTOR 
activation in AU565 parental cells. It is possible that the original findings of FKBP38’s 
inhibitory function on Rheb/mTOR were cell line-specific. The FKBP family has known 
functions in modulating the mTOR family, as FKBP12 binds to the mTOR inhibitor 
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rapamycin, which leads to FKBP12-rapamycin binding to and inhibition of mTORC1 (115, 
116). This indicates that FKBP38 binding to and modulating complexes of mTOR proteins 
is plausible, and further study to define the cell line-specific role of FKBP38 in mTOR 
activation is desirable.  
We observed a large number of copy-number alterations in LapR cells compared to 
parental cells (see Fig. 24, for example). It is likely that the vast majority of these alterations 
are passengers rather than drivers in lapatinib resistance. Indeed, Navin and colleagues have 
shown by single-cell sequencing of cancer cells that individual cancer cells tend to 
stochastically lose or gain large chromosomal regions (117). Some of these are selected for 
during tumor evolution or drug resistance; however, passenger mutations acquired by this 
“genetic drift” also become solidified in clones with higher fitness, which would explain the 
large number of copy-number variations in our LapR cells compared to parental, given the 
genomic instability of cancer cells. 
 The use of lapatinib has decreased in recent years due to its lower efficacy compared 
to trastuzumab and T-DM1 (trastuzumab fused to emtansine). Nonetheless, lapatinib 
resistance mechanisms are likely to apply to trastuzumab (4) and potentially to T-DM1 as 
well.   
 Although targeted therapy combinations may effectively reverse drug resistance, 
identifying orthogonal therapy combinations with non-cross-resistant mechanisms of action 
holds perhaps greater promise. For example, the combinations of targeted therapies, which 
can induce dramatic but short-lived tumor regressions, may be successfully combined with 
immunotherapies, which may act more slowly but have longer-lived responses (118, 119). 
The strength of targeted therapy lies in the ability to rapidly debulk large tumors, especially 
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in treatment-naïve tumors (120, 121). Their weakness lies in the ability of tumors to rapidly 
evolve (51). Thus by using orthogonal therapies in combination with targeted therapies, 
minimal resistant disease may potentially be eliminated. The future of targeted therapy lies 
in identifying rational combinations of targeted therapies with other synergistic therapies 
that can prevent or delay acquired drug resistance. 
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Appendix  
BT474 RPPA Data (Table 1) 
Slide 
No. Filename 
Gene 
Name 
BT474 
Par 
BT474 
LapR 
BT474 Par 
(Normalized) 
BT474 LapR 
(Normalized) 
1 14-3-3_beta-R-V_GBL 9029686 YWHAB 1.013 0.942 1.000 0.930 
2 14-3-3_epsilon-M-C_GBL 9029645 YWHAE 0.689 0.628 1.000 0.911 
3 14-3-3_zeta-R-V_GBL 9029687  YWHAZ 4.711 4.444 1.000 0.943 
5 4E-BP1-R-V_GBL 9029712 EIF4EBP1 1.433 1.657 1.000 1.156 
6 4E-BP1_pS65-R-V_GBL 9029145 EIF4EBP1 2.036 2.073 1.000 1.018 
7 4E-BP1_pT37_T46-R-V_GBL 9029146 EIF4EBP1 4.604 5.710 1.000 1.240 
8 53BP1-R-E_GBL 9029147 TP53BP1 0.786 0.690 1.000 0.878 
9 ACC_pS79-R-V_GBL 9029148 
ACACA 
ACACB 1.115 1.520 1.000 1.364 
10 ACC1-R-E_GBL 9029149 ACACA 13.806 15.578 1.000 1.128 
11 ACVRL1-R-C_GBL 9029150 ACVRL1 0.363 0.242 1.000 0.667 
14 Akt-R-V_GBL 9029709 
AKT1 
AKT2 
AKT3 16.077 11.957 1.000 0.744 
16 Akt_pS473-R-V_GBL 9029710 
AKT1 
AKT2 
AKT3 5.923 7.589 1.000 1.281 
18 Akt_pT308-R-V_GBL 9029711 
AKT1 
AKT2 
AKT3 2.433 2.656 1.000 1.092 
19 alpha-Catenin-M-V_GBL 9029649 CTNNA1 0.581 0.635 1.000 1.093 
20 AMPK_alpha-R-C_GBL 9029167 PRKAA1 1.102 1.077 1.000 0.978 
21 AMPK_pT172-R-V_GBL 9029168 PRKAA1 1.259 1.529 1.000 1.214 
22 Annexin_I-R-E_GBL 9029156 ANXA1 1.088 0.976 1.000 0.897 
23 Annexin_VII-M-V_GBL 9029646 ANXA7  0.601 0.583 1.000 0.970 
24 AR-R-V_GBL 9029157 AR 1.835 1.137 1.000 0.619 
25 Bad_pS112-R-V_GBL 9029158 BAD 0.773 0.743 1.000 0.961 
26 Bak-R-E_GBL 9029159 BAK1 1.133 1.122 1.000 0.990 
27 Bax-R-V_GBL 9029160 BAX 0.840 0.794 1.000 0.945 
28 Bcl-2-M-V_GBL 9029647 BCL2 0.087 0.081 1.000 0.926 
29 Bcl-xL-R-V_GBL 9029161 BCL2L1 0.524 0.489 1.000 0.933 
30 Beclin-G-C_GBL 9029683 BECN1 0.832 0.845 1.000 1.016 
31 beta-Catenin-R-V_GBL 9029171 CTNNB1 0.541 0.534 1.000 0.986 
32 Bid-R-C_GBL 9029163 BID 0.571 0.561 1.000 0.983 
33 Bim-R-V_GBL 9029164 BCL2L11 0.339 0.320 1.000 0.945 
34 c-Kit-R-V_GBL 9029207 KIT 0.318 0.359 1.000 1.130 
35 c-Met-M-E_GBL 9029660 MET 1.365 1.388 1.000 1.017 
36 c-Met_pY1235-R-V_GBL 9029690 MET 1.000 0.974 1.000 0.974 
37 c-Myc-R-C_GBL 9029216 MYC 0.929 0.743 1.000 0.800 
38 C-Raf-R-V_GBL 9029249 RAF1 2.411 2.814 1.000 1.167 
40 C-Raf_pS338-R-E_GBL 9029692 RAF1 0.730 0.903 1.000 1.237 
41 
Caspase-7_cleavedD198-R-C_GBL 
9029170 CASP7 0.489 0.490 1.000 1.002 
42 Caspase-8-M-E_GBL 9029648 CASP8 0.945 0.783 1.000 0.829 
43 Caveolin-1-R-V_GBL 9029172 CAV1 0.083 0.127 1.000 1.539 
44 CD31-M-V_GBL 9029685 PECAM1 0.449 0.464 1.000 1.034 
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Slide 
No. Filename 
Gene 
Name 
BT474 
Par 
BT474 
LapR 
BT474 Par 
(Normalized) 
BT474 LapR 
(Normalized) 
45 CD49b-M-V_GBL 9029651 ITGA2 0.271 0.249 1.000 0.918 
46 CDK1-R-V_GBL 9029173 CDC2 1.391 1.405 1.000 1.010 
48 Chk1-R-E_GBL 9029704 CHEK1 1.160 1.108 1.000 0.956 
49 Chk1_pS345-R-E_GBL 9029175 CHEK1 0.312 0.296 1.000 0.949 
50 Chk2-M-E_GBL 9029652 CHEK2 1.047 1.150 1.000 1.098 
51 Chk2_pT68-R-E_GBL 9029176 CHEK2 0.382 0.424 1.000 1.110 
52 cIAP-R-V_GBL 9029177 BIRC2  1.237 0.976 1.000 0.789 
53 Claudin-7-R-V_GBL 9029178 CLDN7 0.308 0.340 1.000 1.106 
54 Collagen_VI-R-V_GBL 9029179 COL6A1 0.234 0.268 1.000 1.143 
55 Cyclin_B1-R-V_GBL 9029180 CCNB1 3.390 3.771 1.000 1.112 
56 Cyclin_D1-R-V_GBL 9029181 CCND1 0.549 0.536 1.000 0.978 
57 Cyclin_E1-M-V_GBL 9029653 CCNE1 0.443 0.518 1.000 1.168 
58 DJ-1-R-E_GBL 9029182 PARK7 1.594 1.656 1.000 1.039 
59 Dvl3-R-V_GBL 9029183 DVL3 0.699 0.699 1.000 1.001 
60 E-Cadherin-R-V_GBL 9029165 CDH1 0.352 0.393 1.000 1.114 
61 eEF2-R-C_GBL 9029184 EEF2 1.633 2.097 1.000 1.284 
62 eEF2K-R-V_GBL 9029185 EEF2K 1.391 1.852 1.000 1.332 
64 EGFR-R-V_GBL 9029713 EGFR 0.569 0.602 1.000 1.059 
66 EGFR_pY1068-R-C_GBL 9029688 EGFR 1.889 1.712 1.000 0.906 
68 EGFR_pY1173-R-V_GBL 9029714 EGFR 0.865 0.893 1.000 1.033 
69 eIF4E-R-V_GBL 9029189 EIF4E 0.643 0.734 1.000 1.141 
71 eIF4G-R-C_GBL 9029689 EIF4G1 3.826 4.262 1.000 1.114 
72 ER-alpha-R-V_GBL 9029191 ESR1 0.643 0.152 1.000 0.237 
73 ER-alpha_pS118-R-V_GBL 9029192 ESR1 0.158 0.150 1.000 0.951 
74 ERCC1-M-E_GBL 9029654 ERCC1 0.982 0.974 1.000 0.992 
75 FASN-R-V_GBL 9029193 FASN 11.498 8.321 1.000 0.724 
76 Fibronectin-R-V_GBL 9029194 FN1 0.711 0.586 1.000 0.825 
77 FOX03a-R-C_GBL 9029195 FOXO3 0.744 1.086 1.000 1.459 
78 FoxM1-R-V_GBL 9029196 FOXM1 0.812 0.656 1.000 0.808 
79 G6PD-M-V_GBL 9029655 G6PD 0.849 0.415 1.000 0.488 
80 Gab2-R-V_GBL 9029197 GAB2 1.184 1.201 1.000 1.014 
81 GAPDH-M-C_GBL 9029656 GAPDH 1.828 1.701 1.000 0.930 
82 GATA3-M-V_GBL 9029657 GATA3 1.066 1.047 1.000 0.982 
83 GSK3-alpha-beta-M-V_GBL 9029658 
GSK3A 
GSK3B 3.601 3.914 1.000 1.087 
84 
GSK3-alpha-beta_pS21_S9-R-V_GBL 
9029199 
GSK3A 
GSK3B 5.117 6.298 1.000 1.231 
85 GSK3_pS9-R-V_GBL 9029198 
GSK3A 
GSK3B 3.585 4.651 1.000 1.297 
86 HER2-M-V_GBL 9029659 ERBB2 1.247 1.153 1.000 0.925 
87 HER2_pY1248-R-C_GBL 9029200 ERBB2 4.074 3.778 1.000 0.927 
88 HER3-R-V_GBL 9029201 ERBB3 0.587 0.539 1.000 0.918 
89 HER3_pY1298-R-C_GBL 9029202 ERBB3 0.905 0.875 1.000 0.967 
90 IGFBP2-R-V_GBL 9029203 IGFBP2 0.453 0.379 1.000 0.836 
91 INPP4B-G-E_GBL 9029684 INPP4B 2.345 2.316 1.000 0.988 
92 IRS1-R-V_GBL 9029204 IRS1 1.017 1.434 1.000 1.410 
93 
JNK_pT183_pT185-R-V_GBL 
9029205 MAPK8 0.627 0.645 1.000 1.029 
94 JNK2-R-C_GBL 9029206 MAPK9 1.463 1.669 1.000 1.140 
95 K-Ras-M-E_GBL 9029671 KRAS 0.843 0.828 1.000 0.982 
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96 Lck-R-V_GBL 9029208 LCK 0.220 0.225 1.000 1.024 
98 
MAPK_pT202_Y204-R-V_GBL 
9029716 
MAPK1 
MAPK3 0.744 0.905 1.000 1.216 
99 MEK1-R-V_GBL 9029210 MAP2K1 1.417 1.672 1.000 1.180 
100 
MEK1_pS217_S221-R-V_GBL 
9029211 MAP2K1 0.470 0.519 1.000 1.105 
101 MGMT-M-V_GBL 9029661 MGMT 2.224 2.383 1.000 1.071 
102 MIG-6-M-V_GBL 9029663 ERRFI1 1.747 2.056 1.000 1.177 
103 MSH2-M-E_GBL 9029664 MSH2 1.482 1.310 1.000 0.884 
104 MSH6-R-E_GBL 9029213 MSH6 3.510 3.259 1.000 0.928 
105 mTOR-R-V_GBL 9029214 FRAP1 1.781 1.894 1.000 1.063 
107 mTOR_pS2448-R-C_GBL 9029717 FRAP1 1.059 1.038 1.000 0.980 
108 MYH11-R-V_GBL 9029217 MYH11 1.358 2.705 1.000 1.992 
109 N-Cadherin-R-V_GBL 9029166 CDH2 0.258 0.261 1.000 1.012 
110 N-Ras-M-V_GBL 9029672 NRAS 0.711 0.699 1.000 0.982 
114 NDRG1_pT346-R-V_GBL 9029218 NDRG1 1.177 1.678 1.000 1.425 
115 NF-kB-p65_pS536-R-C_GBL 9029220 NFKB1 0.705 0.574 1.000 0.814 
116 NF2-R-C_GBL 9029219 NF2 0.967 0.980 1.000 1.014 
117 Notch1-R-V_GBL 9029221 NOTCH1 0.189 0.238 1.000 1.259 
118 p27-R-V_GBL 9029222 CDKN1B 0.765 0.749 1.000 0.979 
119 p27_pT157-R-C_GBL 9029223 CDKN1B 0.536 0.552 1.000 1.028 
120 p27_pT198-R-V_GBL 9029224 CDKN1B 0.308 0.305 1.000 0.991 
121 p38_MAPK-R-E_GBL 9029225 MAPK14 0.601 0.550 1.000 0.914 
122 p38_pT180_Y182-R-V_GBL 9029226 MAPK14 0.364 0.422 1.000 1.159 
123 p53-R-E_GBL 9029227 TP53 0.217 0.251 1.000 1.153 
124 p70S6K-R-V_GBL 9029228 RPS6KB1 2.422 3.113 1.000 1.285 
125 p70S6K_pT389-R-V_GBL 9029229 RPS6KB1 3.060 3.654 1.000 1.194 
126 p90RSK-R-C_GBL 9029230 RPS6KA1 0.705 0.732 1.000 1.038 
127 
p90RSK_pT359_S363-R-C_GBL 
9029231 RPS6KA1 0.367 0.427 1.000 1.164 
128 PARP_cleaved-M-E_GBL 9029665 PARP1 0.621 0.599 1.000 0.965 
129 Paxillin-R-C_GBL 9029232 PXN 1.281 1.274 1.000 0.995 
130 PCNA-M-C_GBL 9029666 PCNA 1.545 1.399 1.000 0.905 
131 PDCD4-R-C_GBL 9029233 PDCD4 2.072 1.918 1.000 0.926 
132 PDK1-R-V_GBL 9029234 PDK1 0.562 0.624 1.000 1.110 
133 PDK1_pS241-R-V_GBL 9029235 PDK1 1.589 1.820 1.000 1.145 
134 PEA15-R-V_GBL 9029236 PEA15 1.124 1.129 1.000 1.004 
135 PEA15_pS116-R-V_GBL 9029237 PEA15 0.511 0.494 1.000 0.966 
136 PI3K-p110-alpha-R-E_GBL 9029238 PIK3CA  0.634 0.884 1.000 1.394 
137 PI3K-p85-R-V_GBL 9029239 PIK3R1 1.149 1.774 1.000 1.544 
138 PKC-alpha-M-V_GBL 9029667 PRKCA  1.684 1.655 1.000 0.983 
139 PKC-alpha_pS657-R-E_GBL 9029240 PRKCA  0.498 0.583 1.000 1.170 
140 PKC-delta_pS664-R-V_GBL 9029241 PRKCD 0.632 0.670 1.000 1.060 
141 
PKC-pan_BetaII_pS660-R-V_GBL 
9029242 PKC 1.668 1.886 1.000 1.131 
142 PR-R-V_GBL 9029243 PGR 2.002 2.295 1.000 1.147 
143 PRAS40_pT246-R-V_GBL 9029244 AKT1S1 5.257 4.938 1.000 0.939 
144 PTEN-R-V_GBL 9029245 PTEN 6.563 5.038 1.000 0.768 
145 Rab11-R-E_GBL 9029246 
RAB11A 
RAB11B 0.310 0.345 1.000 1.114 
147 Rab25-R-E_GBL 9029691 RAB25 0.625 0.615 1.000 0.984 
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148 Rab25-R-E_GBL 9029248 RAB25 0.518 0.498 1.000 0.962 
149 Rad50-M-E_GBL 9029668 RAD50 1.245 1.316 1.000 1.057 
150 Rad51-M-E_GBL 9029698 RAD51 0.903 0.879 1.000 0.973 
151 Raf-B-M-E_GBL 9029670 BRAF 4.688 4.470 1.000 0.954 
153 Raptor-R-V_GBL 9029693 RPTOR 1.996 2.337 1.000 1.171 
154 Rb-M-E_GBL 9029673 RB1 1.257 1.242 1.000 0.988 
155 Rb_pS807_S811-R-V_GBL 9029252 RB1 2.579 2.681 1.000 1.039 
157 RBM15-R-V_GBL 9029694 RBM15 1.122 1.521 1.000 1.355 
158 Rictor-R-C_GBL 9031266 RICTOR 1.382 1.770 1.000 1.281 
159 Rictor_pT1135-R-V_GBL 9031267 RICTOR 2.529 3.484 1.000 1.378 
161 S6_pS235_S236-R-V_GBL 9031268 RPS6 1.729 1.647 1.000 0.953 
163 S6_pS240_S244-R-V_GBL 9029707 RPS6 3.052 5.491 1.000 1.799 
164 SCD1-M-V_GBL 9029674 SCD1 0.685 0.671 1.000 0.980 
166 SETD2-R-E_GBL 9029696 SETD2 0.275 0.282 1.000 1.027 
167 SF2-M-E_GBL 9029675 SFRS1 1.333 1.430 1.000 1.073 
168 Smac-M-E_GBL 9029676 DIABLO 0.466 0.490 1.000 1.051 
169 Smad1-R-V_GBL 9028812 SMAD1 0.967 1.005 1.000 1.039 
170 Smad3-R-V_GBL 9029627 SMAD3 1.332 1.433 1.000 1.076 
171 Smad4-M-V_GBL 9029677 SMAD4 0.670 0.692 1.000 1.034 
172 Snail-M-E_GBL 9029678 SNAI2 0.564 0.578 1.000 1.025 
173 Src-M-V_GBL 9029679 SRC 0.844 0.989 1.000 1.172 
174 Src_pY416-R-C_GBL 9029628 SRC 1.216 1.139 1.000 0.937 
175 Src_pY527-R-V_GBL 9029629 SRC 0.500 0.528 1.000 1.056 
176 STAT3_pY705-R-V_GBL 9029630 STAT3 1.088 1.001 1.000 0.920 
177 STAT5-alpha-R-V_GBL 9029631 STAT5A 1.487 1.174 1.000 0.789 
178 Stathmin-R-V_GBL 9029632 STMN1 0.578 0.407 1.000 0.705 
180 Syk-M-V_GBL 9029699 SYK 1.882 2.371 1.000 1.260 
181 TAZ-R-V_GBL 9029633 WWTR1 0.912 0.907 1.000 0.995 
182 TIGAR-R-V_GBL 9029634 C12ORF5 1.668 1.761 1.000 1.056 
183 
Transglutaminase-M-V_GBL 
9029681 TGM2 1.026 0.974 1.000 0.949 
185 TRFC-R-V_GBL 9029708 TRFC 0.875 0.902 1.000 1.031 
186 TSC1-R-C_GBL 9029636 TSC1 3.569 3.468 1.000 0.972 
187 TTF1-R-V_GBL 9029637 TTF1 0.841 0.528 1.000 0.628 
188 Tuberin-R-E_GBL 9029638 TSC2 4.915 4.253 1.000 0.865 
189 VEGFR2-R-V_GBL 9029639 KDR 4.986 4.134 1.000 0.829 
191 VHL-M-C_GBL 9029706 VHL 0.333 0.341 1.000 1.024 
193 XRCC1-R-E_GBL 9029705 XRCC1 0.570 0.521 1.000 0.915 
194 YAP-R-E_GBL 9029641 YAP1 1.035 1.109 1.000 1.071 
195 YAP_pS127-R-E_GBL 9029642 YAP1 4.827 4.416 1.000 0.915 
196 YB-1-R-V_GBL 9029643  YBX1 2.476 2.538 1.000 1.025 
197 YB-1_pS102-R-V_GBL 9029644 YBX1 0.973 0.981 1.000 1.008 
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1 14-3-3_beta-R-V_GBL9030279 YWHAB 0.299 0.293 1.000 0.982 
2 
14-3-3_epsilon-M-
C_GBL9030313 YWHAE 0.199 0.187 1.000 0.936 
3 14-3-3_zeta-R-V_GBL9030280 YWHAZ 2.350 2.758 1.000 1.174 
4 4E-BP1-R-V_GBL9030142 EIF4EBP1 1.205 1.361 1.000 1.129 
5 4E-BP1_pS65-R-V_GBL9030143 EIF4EBP1 2.403 2.296 1.000 0.956 
6 
4E-BP1_pT37_T46-R-
V_GBL9030144 EIF4EBP1 4.730 6.122 1.000 1.294 
7 53BP1-R-E_GBL9030235 TP53BP1 0.462 0.527 1.000 1.141 
8 ACC_pS79-R-V_GBL9030145 
ACACA 
ACACB 0.328 0.233 1.000 0.711 
9 ACC1-R-E_GBL9030321 ACACA 3.623 2.387 1.000 0.659 
10 ACVRL1-R-C_GBL9030251 ACVRL1 0.188 0.192 1.000 1.022 
11 Akt-R-V_GBL9030250 
AKT1 
AKT2 
AKT3 4.420 6.485 1.000 1.467 
12 Akt_pS473-R-V_GBL9030147 
AKT1 
AKT2 
AKT3 4.304 4.656 1.000 1.082 
13 Akt_pT308-R-V_GBL9030271 
AKT1 
AKT2 
AKT3 4.282 5.611 1.000 1.310 
14 AMPK_alpha-R-C_GBL9030148 PRKAA1 1.048 1.056 1.000 1.008 
15 AMPK_pT172-R-V_GBL9030149 PRKAA1 1.103 0.935 1.000 0.848 
16 Annexin_VII-M-V_GBL9030302 ANXA7 0.133 0.132 1.000 0.990 
17 AR-R-V_GBL9030210 AR 0.521 0.475 1.000 0.911 
18 B-Raf-M-C_GBL9030306 BRAF 1.283 1.702 1.000 1.327 
19 Bad_pS112-R-V_GBL9030150 BAD 0.666 0.696 1.000 1.045 
20 Bak-R-E_GBL9030151 BAK1 0.698 0.662 1.000 0.949 
21 Bax-R-V_GBL9030152 BAX 0.752 0.884 1.000 1.177 
22 Bcl-2-M-V_GBL9030305 BCL2 0.116 0.111 1.000 0.958 
23 Bcl-xL-R-V_GBL9030154 BCL2L1 0.295 0.320 1.000 1.088 
24 Beclin-G-C_GBL9030336 BECN1 0.257 0.253 1.000 0.983 
25 beta-Catenin-R-V_GBL9030153 CTNNB1 0.329 0.366 1.000 1.115 
26 Bid-R-C_GBL9030155 BID 0.686 0.700 1.000 1.021 
27 Bim-R-V_GBL9030156 BCL2L11 0.312 0.340 1.000 1.089 
28 BRCA2-R-C_GBL9030212 BRCA2 0.089 0.121 1.000 1.358 
29 c-Jun_pS73-R-V_GBL9030161 JUN 0.294 0.341 1.000 1.157 
30 c-Kit-R-V_GBL9030162 KIT 0.220 0.205 1.000 0.932 
31 c-Met-M-E_GBL9030293 MET 0.514 0.496 1.000 0.963 
32 c-Met_pY1235-R-V_GBL9030207 MET 0.721 0.644 1.000 0.894 
33 c-Myc-R-C_GBL9030282 MYC 0.776 1.676 1.000 2.160 
34 C-Raf-R-V_GBL9030218 RAF1 0.826 0.938 1.000 1.136 
35 C-Raf_pS338-R-E_GBL9030163 RAF1 0.392 0.426 1.000 1.086 
36 
Caspase-7_cleavedD198-R-
C_GBL9030157 CASP7 0.186 0.205 1.000 1.103 
37 Caspase-8-M-E_GBL9030298 CASP8 0.938 0.959 1.000 1.022 
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38 Caveolin-1-R-V_GBL9030158 CAV1 0.139 0.131 1.000 0.941 
39 CD31-M-V_GBL9030307 PECAM1 0.051 0.063 1.000 1.242 
40 CD49b-M-V_GBL9030296 ITGA2 0.213 0.225 1.000 1.059 
41 CDK1-R-V_GBL9030237 CDC2 0.693 0.784 1.000 1.131 
42 Chk1-R-E_GBL9030159 CHEK1 0.332 0.318 1.000 0.956 
43 Chk1_pS345-R-C_GBL9030229 CHEK1 0.210 0.221 1.000 1.052 
44 Chk2-M-E_GBL9030283 CHEK2 0.521 0.517 1.000 0.993 
45 Chk2_pT68-R-E_GBL9030160 CHEK2 0.251 0.227 1.000 0.907 
46 Claudin-7-R-V_GBL9030223 CLDN7 0.503 0.653 1.000 1.298 
47 Collagen_VI-R-V_GBL9030275 COL6A1 1.001 1.032 1.000 1.031 
48 Cyclin_B1-R-V_GBL9030164 CCNB1 1.408 1.714 1.000 1.217 
49 Cyclin_D1-R-V_GBL9030276 CCND1 0.598 0.602 1.000 1.008 
50 Cyclin_E1-M-V_GBL9030308 CCNE1 0.398 0.414 1.000 1.041 
51 DJ-1-R-E_GBL9030227 PARK7 2.155 2.233 1.000 1.036 
52 Dvl3-R-V_GBL9030233 DVL3 0.303 0.348 1.000 1.148 
53 E-Cadherin-R-V_GBL9030252 CDH1 0.440 0.443 1.000 1.009 
54 eEF2-R-C_GBL9030241 EEF2 1.426 1.288 1.000 0.903 
55 eEF2K-R-V_GBL9030242 EEF2K 1.333 1.356 1.000 1.017 
56 EGFR-R-V_GBL9030254 EGFR 0.289 0.314 1.000 1.084 
57 EGFR_pY1068-R-C_GBL9030165 EGFR 2.840 2.257 1.000 0.794 
58 EGFR_pY1173-R-V_GBL9030166 EGFR 0.963 0.979 1.000 1.016 
59 eIF4E-R-V_GBL9030206 EIF4E 1.517 1.876 1.000 1.237 
60 eIF4G-R-C_GBL9030257 EIF4G1 1.298 1.385 1.000 1.067 
61 ER-alpha-R-V_GBL9030277 ESR1 0.154 0.165 1.000 1.072 
62 
ER-alpha_pS118-R-
V_GBL9030167 ESR1 0.560 0.514 1.000 0.918 
63 ERCC1-M-E_GBL9030309 ERCC1 0.473 0.468 1.000 0.988 
64 FASN-R-V_GBL9030327 FASN 7.668 7.882 1.000 1.028 
65 Fibronectin-R-V_GBL9030168 FN1 2.682 1.750 1.000 0.653 
66 FoxM1-R-V_GBL9030256 FOXM1 0.319 0.446 1.000 1.397 
67 FOXO3a-R-C_GBL9030255 FOXO3 0.099 0.111 1.000 1.123 
68 G6PD-M-V_GBL9030334 G6PD 3.379 2.803 1.000 0.829 
69 Gab2-R-V_GBL9030234 GAB2 2.335 1.758 1.000 0.753 
70 GAPDH-M-C_GBL9030330 GAPDH 2.717 7.423 1.000 2.732 
71 GATA3-M-V_GBL9030312 GATA3 0.196 0.176 1.000 0.895 
72 
GSK3-alpha-beta-M-
V_GBL9030310 
GSK3A 
GSK3B 1.638 1.498 1.000 0.914 
73 
GSK3-alpha-beta_pS21_S9-R-
V_GBL9030169 
GSK3A 
GSK3B 4.548 3.960 1.000 0.871 
74 GSK3_pS9-R-V_GBL9030248 
GSK3A 
GSK3B 3.298 2.796 1.000 0.848 
75 HER2-M-V_GBL9030319 ERBB2 0.114 0.116 1.000 1.014 
76 HER2_pY1248-R-C_GBL9030325 ERBB2 3.381 3.043 1.000 0.900 
77 HER3-R-V_GBL9030281 ERBB3 0.414 0.458 1.000 1.106 
78 HER3_pY1298-R-C_GBL9030208 ERBB3 0.675 0.577 1.000 0.854 
79 Heregulin-R-V_GBL9030226 NRG1 0.194 0.173 1.000 0.895 
80 IGFBP2-R-V_GBL9030170 IGFBP2 0.810 0.650 1.000 0.803 
81 INPP4B-G-E_GBL9030337 INPP4B 0.800 0.998 1.000 1.247 
82 IRS1-R-V_GBL9030217 IRS1 0.507 0.513 1.000 1.012 
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83 
JNK_pT183_pT185-R-
V_GBL9030225 MAPK8 0.399 0.383 1.000 0.960 
84 JNK2-R-C_GBL9030171 MAPK9 0.876 1.024 1.000 1.169 
85 Lck-R-V_GBL9030172 LCK 0.280 0.247 1.000 0.883 
86 
MAPK_pT202_Y204-R-
V_GBL9030339 
MAPK1 
MAPK3 1.458 1.350 1.000 0.926 
87 MEK1-R-V_GBL9030174 MAP2K1 1.000 1.132 1.000 1.132 
88 
MEK1_pS217_S221-R-
V_GBL9030246 MAP2K1 0.410 0.454 1.000 1.107 
89 MIG-6-M-V_GBL9030300 ERRFI1 0.670 0.690 1.000 1.030 
90 MSH2-M-E_GBL9030294 MSH2 0.965 0.886 1.000 0.918 
91 MSH6-R-E_GBL9030243 MSH6 1.052 0.909 1.000 0.864 
92 mTOR-R-V_GBL9030175 FRAP1 1.432 1.691 1.000 1.180 
93 mTOR_pS2448-R-C_GBL9030176 FRAP1 0.632 0.752 1.000 1.190 
94 MYH11-R-V_GBL9030265 MYH11 0.339 0.439 1.000 1.294 
95 
Myosin_IIA_pS1943-R-
V_GBL9030329 MYH9 1.418 1.091 1.000 0.769 
96 N-Cadherin-R-V_GBL9030177 CDH2 0.146 0.144 1.000 0.984 
97 N-Ras-M-V_GBL9030333 NRAS 0.219 0.214 1.000 0.974 
98 NDRG1_pT346-R-V_GBL9030259 NDRG1 0.215 0.362 1.000 1.684 
99 
NF-kB-p65_pS536-R-
C_GBL9030178 NFKB1 0.164 0.142 1.000 0.869 
100 NF2-R-C_GBL9030240 NF2 0.467 0.469 1.000 1.004 
101 Notch1-R-V_GBL9030244 NOTCH1 0.342 0.650 1.000 1.899 
102 p27-R-V_GBL9030228 CDKN1B 0.248 0.261 1.000 1.053 
103 p27_pT157-R-C_GBL9030222 CDKN1B 1.216 1.245 1.000 1.023 
104 p27_pT198-R-V_GBL9030224 CDKN1B 0.534 0.495 1.000 0.927 
105 p38_MAPK-R-V_GBL9030179 MAPK14 0.674 0.872 1.000 1.295 
106 
p38_pT180_Y182-R-
V_GBL9030180 MAPK14 0.484 0.499 1.000 1.031 
107 p53-R-E_GBL9030181 TP53 0.123 0.140 1.000 1.134 
108 p70S6K-R-V_GBL9030182 RPS6KB1 0.441 0.489 1.000 1.107 
109 p70S6K_pT389-R-V_GBL9030183 RPS6KB1 0.658 0.607 1.000 0.923 
110 p90RSK-R-C_GBL9030211 RPS6KA1 0.949 0.680 1.000 0.717 
111 
p90RSK_pT359_S363-R-
C_GBL9030213 RPS6KA1 0.136 0.408 1.000 2.992 
112 PARP_cleaved-M-E_GBL9030285 PARP1 0.188 0.162 1.000 0.862 
113 Paxillin-R-C_GBL9030184 PXN 0.367 0.359 1.000 0.976 
114 PCNA-M-C_GBL9030311 PCNA 0.452 0.413 1.000 0.914 
115 PDCD4-R-C_GBL9030220 PDCD4 1.682 1.217 1.000 0.724 
116 PDK1-R-V_GBL9030185 PDK1 0.139 0.140 1.000 1.005 
117 PDK1_pS241-R-V_GBL9030186 PDK1 0.786 0.814 1.000 1.036 
118 PEA15-R-V_GBL9030238 PEA15 0.695 0.748 1.000 1.075 
119 PEA15_pS116-R-V_GBL9030239 PEA15 0.166 0.158 1.000 0.954 
120 
PI3K-p110-alpha-R-
C_GBL9030219 PIK3CA  0.897 1.094 1.000 1.220 
121 PI3K-p85-R-V_GBL9030187 PIK3R1 0.687 0.659 1.000 0.960 
122 PKC-alpha-M-V_GBL9030286 PRKCA  0.875 0.594 1.000 0.679 
123 
PKC-alpha_pS657-R-
C_GBL9030188 PRKCA  1.372 0.776 1.000 0.566 
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124 
PKC-delta_pS664-R-
V_GBL9030232 PRKCD 0.245 0.218 1.000 0.888 
125 
PKC-pan_betaII_pS660-R-
V_GBL9030263 PKC 0.664 0.750 1.000 1.131 
126 PR-R-V_GBL9030189 PGR 0.154 0.139 1.000 0.903 
127 
PRAS40_pT246-R-
V_GBL9030209 AKT1S1 2.253 1.733 1.000 0.769 
128 PTEN-R-V_GBL9030191 PTEN 1.028 1.207 1.000 1.174 
129 Rab11-R-E_GBL9030249 
RAB11A 
RAB11B 0.216 0.224 1.000 1.039 
130 Rab25-R-E_GBL9030192 RAB25 0.313 0.288 1.000 0.921 
131 Rab25-R-V_GBL9030270 RAB25 0.159 0.158 1.000 0.994 
132 Rad50-M-V_GBL9030299 RAD50 1.418 1.250 1.000 0.882 
133 Rad51-M-E_GBL9030288 RAD51 0.783 0.763 1.000 0.975 
134 Raptor-R-V_GBL9030260 RPTOR 1.270 1.341 1.000 1.056 
135 Rb-M-E_GBL9030287 RB1 0.374 0.315 1.000 0.842 
136 
Rb_pS807_S811-R-
V_GBL9030190 RB1 1.536 1.077 1.000 0.701 
137 RBM15-R-V_GBL9030264 RBM15 0.570 0.699 1.000 1.227 
138 Rictor-R-C_GBL9030261 RICTOR 0.645 0.902 1.000 1.397 
139 Rictor_pT1135-R-V_GBL9030262 RICTOR 0.947 1.113 1.000 1.176 
140 
S6_pS235_S236-R-
V_GBL9030193 RPS6 3.646 3.091 1.000 0.848 
141 
S6_pS240_S244-R-
V_GBL9030194 RPS6 0.798 0.691 1.000 0.866 
142 SCD1-M-V_GBL9030332 SCD1 0.204 0.198 1.000 0.969 
143 SETD2-R-E_GBL9030324 SETD2 0.102 0.100 1.000 0.978 
144 SF2-M-V_GBL9030301 SFRS1 0.090 0.095 1.000 1.047 
145 Smac-M-E_GBL9030289 DIABLO 0.326 0.357 1.000 1.095 
146 Smad1-R-V_GBL9030231 SMAD1 0.510 0.586 1.000 1.147 
147 Smad3-R-V_GBL9030216 SMAD3 1.059 1.026 1.000 0.969 
148 Smad4-M-V_GBL9030317 SMAD4 0.114 0.111 1.000 0.970 
149 Snail-M-E_GBL9030331 SNAI2 0.376 0.381 1.000 1.013 
150 Src-M-V_GBL9030291 SRC 0.712 0.617 1.000 0.866 
151 Src_pY416-R-C_GBL9030195 SRC 1.321 1.094 1.000 0.828 
152 Src_pY527-R-V_GBL9030196 SRC 1.087 0.968 1.000 0.891 
153 STAT3_pY705-R-V_GBL9030199 STAT3 0.438 0.425 1.000 0.970 
154 STAT5-alpha-R-V_GBL9030200 STAT5A 0.477 0.554 1.000 1.161 
155 Stathmin-R-V_GBL9030205 STMN1 0.586 0.520 1.000 0.886 
156 Syk-M-V_GBL9030318 SYK 0.363 0.190 1.000 0.522 
157 TAZ-R-V_GBL9030340 WWTR1 0.664 0.625 1.000 0.942 
158 TIGAR-R-V_GBL9030253 C12ORF5 0.843 1.334 1.000 1.583 
159 
Transglutaminase-M-
V_GBL9030295 TGM2 0.692 0.654 1.000 0.945 
160 TRFC-R-V_GBL9030266 TRFC 0.225 0.542 1.000 2.405 
161 TSC1-R-C_GBL9030258 TSC1 1.680 1.845 1.000 1.098 
162 TTF1-R-V_GBL9030247 TTF1 0.460 0.453 1.000 0.985 
163 Tuberin-R-V_GBL9030201 TSC2 1.471 1.457 1.000 0.990 
164 
Tuberin_pT1462-R-
V_GBL9030202 TSC2 0.327 0.360 1.000 1.100 
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165 VEGFR2-R-V_GBL9030203 KDR 1.321 0.886 1.000 0.671 
166 VHL-M-C_GBL9030292 VHL 0.875 1.833 1.000 2.094 
167 XRCC1-R-E_GBL9030230 XRCC1 0.145 0.142 1.000 0.980 
168 YAP-R-E_GBL9030278 YAP1 0.278 0.280 1.000 1.005 
169 YAP_pS127-R-E_GBL9030215 YAP1 0.493 0.540 1.000 1.096 
170 YB-1-R-V_GBL9030204 YBX1 1.554 1.114 1.000 0.717 
171 YB-1_pS102-R-V_GBL9030221 YBX1 0.814 0.691 1.000 0.849 
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